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SUMMARY
The purpose of the work contained in this thesis is to investigate the 
aetiology of upper gastrointestinal disease in renal transplant recipients. 
It has been recognised for almost thirty years that transplant recipients 
suffer from a high prevalence of peptic ulceration and a high incidence of 
the complications of peptic ulceration. The aetiology of this problem 
remains unclear despite many studies which have attempted to define a 
cause.
These studies have concentrated primarily on the role of gastric acid 
secretion and the contribution of factors such as hypercalcaemia 
hypergastrinaemia and corticosteroids. Some increase in gastric acid 
secretion has indeed been demonstrated although these differences have not 
been consistent and are not markedly different from the pattern of gastric 
acid secretion in patients on haemodialysis. Similarly the importance of 
corticosteroids remains unclear.
In this thesis the specific aetiological factors studied were 
Helicobacter pylori, Cytomegalovirus and Herpes Simplex virus. 
Helicobacter pylori has been the cause of much interest in the field of 
peptic ulceration over the past eight years and its role in the aetiology of 
peptic ulceration and gastritis is a source of continuing debate, although 
the organism has not been previously investigated in transplant recipients. 
Cytomegalovirus has been implicated in case reports and uncontrolled series 
as a cause of peptic ulceration in transplant recipients. However the 
prevalence of the virus in the gastrointestinal tract of normal individuals 
is unknown and, because of this, its role as a pathogen in transplant 
recipients is still to be defined. Lastly Herpes simplex has been suggested 
as a cause of peptic ulceration in the general population although this is
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based on indirect evidence and there are no reports of the isolation of the 
virus from peptic ulcers. Herpes simplex has been identified in association 
with oesophagitis in both immunocompetent and im munosuppressed 
individuals but has not been reported in the gastroduodenal mucosa except 
on rare occassions.
The study described in this thesis was performed on an unselected group 
of renal transplant recipients and on control tissue from non transplant 
patients. The study group underwent upper gastrointestinal endoscopy at 
between two and four months after transplantation. All endoscopic 
abnormalities were documented, and biopsy material was obtained from the 
gastroduodenal mucosa and stored for subsequent laboratory analysis.
The biopsy material was examined histologically to assess the degree of 
gastritis and duodenitis and to detect the presence of Helicobacter pylori. 
The presence of Cytomegalovirus and Herpes Simplex was determined by 
immunohistochemistry. T lymphocyte subpopulations were assessed in the 
gastroduodenal mucosa of transplant recipients and control patients by 
immunohistochemistry in an attempt to elucidate the local immunological 
response to infection particularly with Helicobacter pylori.
Symptomatic dyspepsia was identified in 60$ of the study group. 
Peptic ulceration was present in 12$ and a striking feature was the high 
prevalence of mucosal inflammatory lesions without ulceration. Duodenitis 
was identified in 48$ and gastritis in 30$. In total 72$ of the study group 
had one or more abnormality of the upper GI tract.
Helicobacter pylori was identified in 48$ and was strongly associated 
with gastritis, with gastric ulceration and with symptomatic dyspepsia. 
There was a tendency for Helicobacter infection to be associated with a 
higher serum urea and creatinine and with a higher prednisolone dose
15
although these differences did not achieve statistical significance. 
Infection with Helicobacter pylori was independent of age and time elapsed 
since transplantation.
Cytomegalovirus was identified in 4855 of the study group, but was only 
present in 1155 of the biopsies from the control group. Infection was 
significantly associated with duodenitis, but no association could be found 
with other pathological processes or with symptomatic dyspepsia. 
Cytomegalovirus was not related to renal function or immunosuppression and 
was independent of age and time elapsed since transplantation.
Herpes simplex could not be identified in any of the biopsy material 
fhom either the study group or the control group and could not implicated 
in any disease process in the upper gastrointestinal tract.
Analysis of mucosal T lymphocyte subsets revealed a tendency towards 
an increase in the the Leu2 subset associated with Helicobacter pylori 
infection, but this did not achieve statistical significance.
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PART I
INTRODUCTION AND METHODS
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PEPTIC ULCER DISEASE IN RENAL TRANSPLANT RECIPIENTS
Peptic ulceration and related pathologies such as gastritis and 
duodenitis are known to occur with increased frequency in transplant 
recipients. Some studies have reported the prevalence of peptic 
ulcer to be as high as 22% (1). In the early days of renal
transplantation a high prevalence of peptic ulceration and a high 
incidence of the complications of peptic ulceration was recognised. 
In 1969 Moore & Hume reported on 14 peptic ulcers in 113 transplant 
recipients, a prevalence of \2% (2). Twelve of these patients 
presented with upper GI haemorrhage resulting in a fatal outcome in 
seven (58?S). Two years later Libertino et al reported on 6 peptic 
ulcer haemorrhages, occurring in 184 transplant recipients with a 
fatal outcome in 5 (83^), confirming the high mortality in this group 
of patients (3). In the same year Hadjiyanakis reported 16 peptic 
ulcers in 139 transplant recipients with haemorrhage in 6 patients 
all of whom died (4).
The magnitude of the problem led many transplant centres to 
consider routine vagotomy prior to transplantation in all patients. 
Other centres adopted a more selective policy, advocating vagotomy 
only in those with a previous history of peptic ulceration or those 
demonstrated to have a peptic ulcer prior to transplantation (5). 
Other groups advocated gastric ulcer surgery in patients with gastric 
acid hypersecretion (6).
During the following decade upper gastrointestinal endoscopy 
became widely available as an investigative technique and, in 
addition to peptic ulcers, some of these patients were demonstrated 
to suffer from gastritis and duodenitis (7,8). There were also
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continued reports of peptic ulcer haemorrhage occurring in between 7 
and 25$ of patients although with an improved mortality, perhaps 
reflecting an improvement in the clinical condition of transplant 
recipients, or improvements in the management of peptic ulcer 
haemorrhage (5,7).
More recently there have been suggestions that the problem is 
decreasing in importance. Knechtle et al demonstrated a fall in the 
prevalence of peptic ulcer from 10.3% in the period 1965-1974 to 5.6$ 
in the period 1975-1984, accompanied by a fall in mortality from 40$ 
to 23$ (9). The same group also reported a decreasing incidence of 
peptic ulcer perforation over the same period of time (10). In 1984 
Cohen reported only 8 peptic ulcers in a population of 573 renal 
transplant recipients (1.3$) (11). This apparent decrease has not 
been uniformly reported however and one recent publication from 1989 
has reported a prevalence of 24$ in an unselected group of transplant 
recipients (12). If the improved diagnostic accuracy of endoscopy is 
considered, however, the prevalence of peptic ulceration would appear 
to be decreasing and certainly the incidence of complications is 
decreasing.
The development of peptic ulceration and related conditions 
appears to occur fairly rapidly following transplantation. Many of 
the reports discussed above were retrospective and precise details of 
the timescale are not available. Petersen et al reported GI 
haemorrhage at a mean of 60 days post-transplantation (13), and 
Knechtle reported 25$ of perforations occuring within 30 days of 
transplantation, although in this report the range was wide (4 days 
to 10 years) (10). Prospective studies have demonstrated a
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remarkably rapid development of peptic ulceration often within days 
of transplantation. Timoney et al demonstrated 5 peptic ulcers by 
endoscopy at a mean of 13 days post-transplant (range 8-22 days) 
(12). Schiessel et al excluded patients with gastroduodenal lesions 
and performed endoscopy on the remaining patients after 3 days and 
again at 4 weeks (7). At the 3 day endoscopy they found 9 ulcers or 
erosions in 55 patients and at 4 weeks identified lesions in a 
further 5 patients. It is perhaps difficult to explain the 
development of these lesions within such a short period of time, 
although it is possible that operative stress and high dose 
immunosuppression are important factors. It is also possible that 
the aetiology of ulceration in the immediate post-transplant period 
is different from the aetiological factors producing ulceration 
several months after transplantation.
A further possible explanation is that many of these lesions 
were present prior to transplantation and are indicative of the high 
prevalence of upper gastrointestinal lesions which are known to occur 
in patients with renal failure (14,15). Alijani et al reported upper 
GI lesions in 10 of 13 patients (76%) who were endoscoped immediately 
prior to transplantation (16). This, however, would not explain the 
findings reported above by Schiessel where patients with known upper 
gastrointestinal disease were excluded from the study (7).
Elucidating the aetiology of peptic ulceration is complicated 
by the many variables present in the transplant population when 
compared with normal controls, or the same patients prior to 
transplantation. The possible aetiological factors proposed have 
fluctuated in popularity along with changing theories as to the
21
pathogenesis of peptic ulceration in the general population. In the 
1 960 's and 1970's attention was focussed primarily on gastric acid 
secretion (1,5) and factors which might affect gastric acid secretion 
such as hypercalcaemia and steroid administration. This latter 
factor has also been implicated because of its effects on the gastric 
mucosal barrier (17). More recently viruses, particularly 
cytomegalovirus and Herpes simplex, have been implicated (8,11,18,19) 
and it would perhaps now be relevant to consider Helicobacter pylori 
as a further possible aetiological agent. The importance of these 
factors, acid secretion and steroid administration will be discussed 
now and infective agents will be discussed in the following chapter.
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THE ROLE OF ACID SECRETION
Early in the history of renal transplantation it was 
established that gastric acid secretion was increased in transplant 
recipients when compared with the normal population. This was 
obviously in keeping with accepted theories as to the pathogenesis of 
peptic ulceration in the general population and the knowledge that 
corticosteroids increase the parietal cell mass and thus increase 
gastric acid secretion (20,21).
Canavan et al studied gastric acid secretion in 10 patients 
prior to transplantation and repeated the studies in the same 
patients 3 months after transplantation (5). A standard pentagastrin 
test demonstrated elevated basal acid output (BAO) and maximal acid 
output (MAO) in haemodialysis patients but with no significant rise 
after transplantation. Maximal acid concentration was also higher 
and did not change significantly after transplantation.
A similar study was performed by Chisholm (1). Twenty five 
patients underwent stimulated gastric secretion studies either by 
histamine infusion or pentagastrin before and after transplantation. 
This study demonstrated a non-significant rise in BAO following 
transplantation in men and women and a significant rise in peak acid 
output (PAO) in men only, 6 weeks after transplantation. The authors 
however could find no correlation between this rise and an increased 
risk of developing peptic ulceration and they concluded that gastric 
secretion studies should not be used to select patients for 
prophylactic vagotomy.
More recent work by Doherty studied PAO in dialysis and 
transplant patients (22). This study reported elevated PAO in 4 2$ of
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36 dialysis patients and in 29$ of 38 transplant recipients. The 
same paper reported a progressive fall in PAO with time following 
transplantation, which was independent of age but not steroid dosage.
It seems clear from the above reports that increased acid 
secretion in transplant recipients has to be interpreted in the light 
of gastric acid secretion in chronic renal failure and during 
haemodialysis. It is known that patients with chronic renal failure 
and patients undergoing haemodialysis have an increased risk of 
developing peptic ulceration. Shepherd demonstrated 9 ulcers in a 
group of 15 haemodialysis patients (60%) (14), and Ventkatesweran 
found 6 ulcers in 13 haemodialysis patients (46>6) (15). This 
obviously represents a much higher prevalence of peptic ulcer than in 
any of the reports relating to transplant recipients. These high 
percentages have not been borne out by other studies however. 
Chisholm found only one definite duodenal ulcer and one equivocal 
abnormality in 35 haemodialysis patients {5.1%) (1), and Gordon 
found 5 duodenal ulcers in 55 patients (9?) (6). The latter study 
included chronic renal failure patients prior to dialysis and may not 
be strictly comparable to the other three reports.
The data on acid secretion in chronic renal failure are also
conflicting. Both of the reports by Canavan (5), and Chisholm (1),
demonstrated an elevated BAO and MAO in pre-transplant patients on 
haemodialysis, compared with normal control values. These findings 
are supported by those of Shepherd and Ventkatesweran (14,15). The
latter study also demonstrated no significant difference in gastric
acid secretion between dialysed and non-dialysed patients with 
chronic renal failure.
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Gordon et al studied 56 patients on haemodialysis. They found 
an elevated MAO in women but not in men and could identify no 
significant change in gastric acid secretion before and after 
dialysis (6). These results however include 6 males who were 
achlohydric. This finding of achlorhydria was also noted by 
McConnell in 10 of 25 patients with chronic renal failure (23). The 
authors also demonstrated a gradual return to normal over a period of 
months following the commencement of haemodialysis. In some of these 
patients they obtained histology of the gastric mucosa consistent 
with atrophic gastritis, although parietal cell antibodies were 
negative.
On balance it would seem that dialysis patients have a gastric 
acid secretion pattern similar to that of transplant recipients and 
have an increased risk of peptic ulceration. There is however, some 
evidence to suggest that the risk of ulceration is even greater in 
these patients following transplantation. Schiessel found 14 
patients with ulcers or erosions in 55 patients who had a normal 
upper GI endoscopy prior to transplantation and Walter et al 
identified upper GI bleeding in 12 of 47 transplant recipients who 
had no ulceration prior to transplantation (7,24).
Indirect evidence on the role of gastric acid secretion can be 
gained from studies on the prevention of peptic ulceration by acid 
inhibition. Jones et al, in 1978, reported a benefit from cimetidine 
administration in decreasing the risk of GI bleeding (25). The 
source of the bleeding however was not identified and the study 
employed a historical control group. Similarly Garvin in 1982 
reported a decrease in upper GI tract complications when cimetidine
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was administered routinely (26). This however was a retrospective 
analysis and other variables such as the immunosuppressive regime 
were not considered and neither of these reports conclusively prove 
that acid inhibition decreases the risk of GI bleeding and peptic 
ulceration.
Schiessel reported the results of a randomised trial of 
cimetidine versus placebo in renal transplant recipients and failed 
to demonstrate, by regular endoscopy, any decrease in the risk of 
peptic ulceration (7). Walter et al performed a similar randomised 
study in 97 transplant recipients (24). They demonstrated a highly 
significant reduction in GI bleeding in the cimetidine treated group. 
This study however was criticised by Doherty who pointed out that 
the source of bleeding in these patients was not identified and that 
the study excluded patients with peptic ulceration prior to 
transplantation (27).
The aetiology of abnormal gastric acid secretion is also the 
subject of some debate. The hypochlorhydria in patients with chronic 
renal failure, particularly in those prior to dialysis is reported 
to be due to atrophic gastritis (6,23). No satisfactory explanation 
for this phenomenon has been advanced however. Gordon et al found 
that all of the achlorhydric patients had negative parietal cell 
antibody titres, suggesting that this is not the autoimmune atrophic 
gastritis seen in the normal population (6). Another explanation, 
advanced by Doherty, is that hydrolysis of urea in the gastric mucosa 
to ammonia would neutralise gastric acid (22), but this does not 
explain the gastritis, which by itself would explain the 
hypochlorhydria (28).
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In the group with hypersecretion it seems likely that the 
elevated serum gastrin, which is known to occur in renal failure (29) 
and which is unaffected by haemodialysis, is responsible. It is 
therefore reasonable to suggest that haemodialysis may improve the 
factors responsible for gastritis while not affecting the serum 
gastrin, explaining the higher gastric acid secretion in 
haemodialysis patients. Following transplantation the serum gastrin 
will return to normal (30) and one would expect gastric acid 
secretion to return to normal. Many studies, however, have 
demonstrated increased gastric acid secretion several months after 
transplantation (1,5). A possible explanation for this is the 
trophic affect of gastrin on the parietal cell mass (31), resulting 
in a gradual decrease in gastric acid secretion following removal of 
the gastrin stimulus. As described by Doherty this does indeed occur 
over a period of several months (22).
Another factor which has been proposed as a possible 
aetiological agent is hypercalcaemia, which has long been recognised 
as a stimulus to gastric acid secretion (32). The role of 
hypercalcaemia in stimulating acid secretion in dialysis and 
transplant patients has only been superficially investigated, 
although neither Chisholm nor Gordon could find a correlation between 
gastric acid secretion and serum calcium (1,6).
Recent work by Timoney et al examined the role of histamine in 
stimulating gastric acid secretion in transplant recipients (12) 
based on reports that duodenal ulcer in non-transplant patients was 
associated with low levels of histamine in the gastric mucosa 
(33,34). They reported a low level of mucosal histamine in 25
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transplant recipients compared with normal controls and these were 
similar to levels in non-transplant patients with duodenal ulcer. 
They could not, however, demonstrate a significant difference between 
mucosal histamine levels in transplant patients with duodenal ulcer 
and those without duodenal ulcer. They also found an elevated serum 
histamine in transplant patients with duodenal ulcer when compared to 
those without. The significance of these findings, however, are 
unclear and the reason for depleted mucosal histamine and the high 
level of circulating histamine have not been explained. It has been 
suggested in other reports that gastrin may be responsible for 
elevation of serum histamine (34) and hypergastrinaemia, although 
present in renal failure, will return to normal after transplantation 
(30). Other possibilities are that high circulating histamine may be 
related to diminished renal function since the kidney is high in 
histamine methyl transferase. Timoney, however, could find no 
correlation between histamine levels and serum creatinine, and the 
transplanted kidney should restore histamine methyl transferase 
activity.
The last aetiological factors to be considered are 
corticosteroids which may increase the parietal cell mass (20,21) or 
stimulate histamine release (12). There is however conflicting 
evidence to incriminate steroids as a cause of gastric hypersecretion 
in renal transplant recipients since neither Canavan nor Chisholm 
found any correlation between acid secretion and steroid dosage 
(1,5), although this was not in accord with the conclusions of 
Doherty (17,27,40). The subject of steroids in the pathogenenesis of 
peptic ulceration will be discussed in more detail later in this
28
chapter.
In conclusion, the relationship of well documented gastric 
hypersecretion to peptic ulcer development is difficult to evaluate. 
It is true that the gastric secretory tests show an elevated MAO and 
PAO following transplantation, but most studies have shown that the 
level is no greater than in the same patients prior to 
transplantation. There also appears to be no relationship between 
acid hypersecretion and the subsequent development of peptic 
ulceration. The situation may be further confused by the different 
methods used to stimulate gastric acid secretion by the inclusion of 
pre-transplant patients both on and off dialysis and by the different 
time intervals between transplantation and assessment of acid 
secretion.
The evidence that reducing acid secretion by the administration 
of H2 antagonists is also weak; many of the studies were 
retrospective or used historical controls, and excluded patients with 
known pathology. Gastric acid hypersecretion, therefore, may be one 
factor in the high prevalence of peptic ulceration, it seems unlikely 
that it is the only one.
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THE ROLE OF CORTICOSTEROIDS
It has been recognised for many years that corticosteroids 
cause peptic ulceration and this has become a widely held belief 
within the medical profession over the past 30 years (35,36). It is 
considered that the presence of an active ulcer or a history of 
dyspepsia or peptic ulceration are relative contraindications to 
corticosteroid administration.
A critical review of the literature, however, suggests that the 
situation is not as clear cut as may be apparent. In 1976 Conn and 
Blitzer conducted a meta analysis of 26 double blind studies 
examining the complications of steroid administration totalling 3558 
patients (37). They were unable to demonstrate a significant 
difference in the occurrence of peptic ulcer in the steroid treated 
groups (1.4?) as compared to the control groups (1$). They were also 
unable to demonstrate any increase in the risk of haemorrhage or 
perforation. The same study also analysed 16 controlled non-double 
blind studies with similar conclusions. The only exception was a 
significantly increased risk of ulceration in those receiving more 
than 1g of prednisolone as a total dose (5.3?).
In a more recent report Messer et al performed a similar 
analysis and reported a highly significant association between peptic 
ulceration and steroid administration with 0.2? in control groups and 
1.5? in the steroid treated groups (38).
In response to this Conn and Poynard re-analysed the 
methodology and the reports by Messer and came to surprisingly 
different conclusions (39). In the 71 studies analysed by Messer, 
Conn considered that 28 had to be excluded because of the
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administration of concurrent medication, the recent use of steroids, 
concurrent use of antacids, inclusion of uncontrolled groups and 
protocol violation prior to randomisation. They then re-calculated 
the data with these studies excluded and found no association between 
peptic ulcer and steroid administration.
It is obvious that the causative role of steroids in peptic 
ulceration is unclear. It is also obvious that a prospective study 
of steroid administration purely to look at the complications is not 
feasible. This therefore means that analyses of therapeutic studies 
have to be undertaken, a practice which is not ideal for several 
reasons. Firstly it cannot be assumed that these therapeutic studies 
have reliably looked for or have documented peptic ulceration and 
secondly the underlying disease process or administration of other 
drugs may be associated with a high risk of peptic ulceration.
In transplant recipients no studies have been performed to 
assess this risk and information must be gleaned from reports of 
peptic ulceration in groups receiving different doses of 
corticosteroids. Chisholm found no correlation between steroid dose 
and either peptic ulceration or symptomatic dyspepsia (1), a finding 
similar to that of Timoney who could determine no relationship 
between the dose of steroids and the risk of developing peptic ulcer 
(12). Canavan and Briggs studied gastric acid secretion before and 
after transplantation and concluded that steroid administration did 
not increase BAO or MAO (5). This conclusion however did not make 
allowance for the known increase in acid secretion during 
haemodialysis (6,14) and it is difficult to separate the effects of 
steroid administration from those of improved renal function,
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surgical stress and immunosuppressive therapy.
These findings however are at variance with those of Doherty in 
1979 who found a positive correlation between steroid dosage and PAO 
and who concluded that most peptic ulcers occurring post-transplant 
were steroid induced exacerbations of pre-existing disease (40).
Other authors have shown a decrease in peptic ulceration 
accompanying decreasing corticosteroid dosage. Knechtle et al 
demonstrated a fall in peptic ulceration from 10.3$ to 5.6$ in two 
concurrent decades, associated with a reduction in steroid dosage 
over this time period (9). The same period however also encompassed 
the change from azathioprine to cyclosporine and was accompanied by 
aggressive pre-transplant treatment of ulcers reported in the second 
decade. Other variables such as pre-transplant health of the patients 
may also be important. It is therefore difficult to be certain that 
the improvement was due solely to a reduction in the dose of 
corticosteroids.
The possible mechanism of action of steroids in ulceration may 
be due either to increased acid secretion or to possible effects on 
the gastroduodenal mucosal barrier. There is certainly a wealth of 
experimental evidence to suggest that increased acid secretion does 
occur with corticosteroid administration due to its trophic effect on 
the parietal cell mass (20,21) although, as discussed previously, 
this phenomenon could also be explained by the trophic effect of 
gastrin (31). Canavan and Briggs could not demonstrate any 
relationship between acid output and the dose of steroid administered 
(5). Doherty, however, did find a weak correlation between PAO and 
prednisolone dosage, although this was not independant of time
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elapsed since transplantation (22).
Corticosteroids have also been reported to have a direct effect 
on the gastroduodenal mucosa by decreasing the rate of turnover of 
the epithelium. Max & Menguy demonstrated a decrease in the mitotic 
rate of gastric mucosal cells with ACTH administration (41) which 
will inhibit the healing response of the gastric mucosa (42) and may 
promote the action of acid and pepsin on small mucosal lesions 
(43).
It is difficult to ascertain the true importance of 
corticosteroid administration. There is obvious experimental 
evidence to show its effect on acid secretion and on the gastric 
mucosal barrier but this does not appear to be borne out by its 
effect on peptic ulceration in the normal population. The evidence 
of its effect on transplant recipients would tend to suggest that the 
dose of corticosteroids does not appear to increase the risk of 
peptic ulceration although this is disputed by some authors (40). 
Certainly it appears to have a minimal effect on gastric acid 
secretion although this has to be interpreted in the knowledge that 
other mechanisms such as a general improvement in patient health and 
resolution of hypergastrinaemia will have a tendency to decrease 
acid secretion. It is also, of course, impossible to separate the 
effect on acid secretion and/or the gastric mucosal barrier from the 
immunosuppressive effect of corticosteroids and the immunosuppressive 
effect of concomitantly administered drugs which will be discussed in 
the following chapter.
A further factor to be taken into account is the difference in 
prevalence of peptic ulceration between transplant recipients and non
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transplant patients on corticosteroids. In most reported series the 
prevalence of peptic ulcer in transplant recipients has been between 
10$ and 25$, whereas even in the high dose steroid group reported by 
Conn and Blitzer the prevalence was only 5.3$ (37), and in most 
reports is around 1$ (38,39)
This group of patients obviously have many other variables as 
discussed above which may contribute to the increased prevalence of 
peptic ulceration. The balance of evidence would suggest that the 
role of corticosteroids is likely to be a small one and does not 
account for the high prevalence of peptic ulcer and the high 
incidence of complications witnessed in this group (37).
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CHAPTER 2
INFECTIOUS AGENTS IN PEPTIC ULCERATION
A. HELICOBACTER PYLORI
B. CYTOMEGALOVIRUS
C. HERPES SIMPLEX VIRUS
D. IMMUNOSUPPRESSION IN TRANSPLANT RECIPIENTS
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HELICOBACTER PILORI
Reports of curved or spiral bacteria in the upper GI tract were 
recognised as early as 1939 (44), but it was not until the work of 
Warren and Marshall in the early part of the last decade that their 
possible significance as a pathogen was appreciated (45). The 
organism was initially described as a Campylobacter like organism 
(CLO), was named Campylobacter pyloridis in 1984 (46) and
subsequently renamed Campylobacter pylori (47). Last year a further 
change was made, creating a new genus, and the organism is now known 
as Helicobacter pylori (48). Since these initial reports many groups 
have studied the organism and it has been implicated in the 
pathogenesis of gastritis, duodenal ulceration and gastric 
ulceration.
Microbiology
The organism is a curved or spiral microaerophilic gram 
negative bacillus (49). One of the most striking features are the 
enzymes produced by the organism, which include extracellular 
catalase and superoxide dismutase which may confer resistance to the 
oxidative enzymes of macrophages (50). A further important enzyme is 
a pre-formed urease which is present in high concentrations and will 
hydrolyse urea to ammonia (51). The resulting alkaline 
microenvironment may protect the organism from the acidic environment 
of the upper gastrointestinal tract. The bacterium appears to have a 
specific affinity for gastric antral type mucosa and is highly motile 
in the viscus environment of the gastric mucus layer (52) (Figs 1&2).
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Figure 1: Transmission electron micrograph of H pylori (arrowed).
Figure 2: Scanning electron micrograph of H pylori within the
strands the gastric mucus layer.
Gastritis and non-ulcer dyspepsia
Definitions
In order to understand the relationship of H pylori to 
gastritis and non-ulcer dyspepsia it is first necessary to define the 
terms. Gastritis is usually viewed as one of three types. Type A 
gastritis affects the body of the stomach and is associated with 
destruction of parietal cells, the presence of parietal cell 
antibodies, intrinsic factor depletion, pernicious anaemia and 
achlorhydria as described by Strickland and McKay (53). The same 
authors described an anatomically, histologically and aetiologically 
distinct type of gastritis, termed Type B gastritis. In contrast to 
Type A Type B affects the mucus secreting cells of the gastric antrum 
without involvement of the body of the stomach and is not associated 
with autoantibodies or pernicious anaemia. Although achlorhydria has 
been reported in Type B gastritis it is not common and usually only 
accompanies the more severe form of the disease (54). A third type 
of gastritis recognised more recently is associated with alkaline 
reflux and resultant intestinal metaplasia (55).
The relationship between non-ulcer dyspepsia and gastritis is a 
complex one. Non-ulcer dyspepsia can be broadly defined as the 
presence of dyspepsia in the absence of ulceration. It is possible 
to subdivide these patients into those with gastritis and those 
without gastritis (56). It has however been reported by Talley that 
gastritis correlates poorly with symptoms of non-ulcer dyspepsia (57) 
and may be reflected in the scepticism with which some clinicians 
view gastritis as a cause of dyspepsia (49). A further factor to be 
considered is the poor correlation between endoscopic appearances and
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histological evidence of gastritis (58) and it is important therefore 
to obtain histology of the gastric mucosa before assigning a patient 
to the non-gastritis group (59).
Gastritis
Since Warren and Marshall’s first report in 1984 the 
association of H pylori with gastritis has been confirmed by many 
authors. The organism has been identified in 89-97$ of patients with 
type B gastritis (60,61 ,62) and the organism was not identified in 
patients with a histologically normal gastric mucosa. In some 
instances H pylori has been identified in an apparently normal mucosa 
in the body of the stomach, but is invariably associated with 
gastritis in the antrum (49). It has also been demonstrated that the 
organism is only identified in gastric type mucosa and is absent from 
areas of intestinal metaplasia (49).
Studies of H pylori in other types of gastritis have shown a 
much lower prevalence. O'Connor reported H pylori in only 21$ of 
patients with Type A gastritis but in 85$ of patients with duodenal 
ulcer and Type B gastritis (63). At present no association between H 
pylori and reflux gastritis has been demonstrated (64). In spite of 
the strong association between Type B gastritis and H pylori,however, 
many clinicians remain sceptical of its importance as a pathogen 
(65). Evidence to support a primary pathogenic role comes from work 
demonstrating primary infection in previously normal individuals, 
improvement in gastritis following eradication of the bacteria and 
ultrastructural changes in the gastric mucosa associated with 
Helicobacter infection. The first two will now be discussed and the
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latter will be dealt with under a separate heading.
In 1978, before the recognition of the possible pathogenicity 
of H pylori, 17 healthy volunteers undergoing gastric pH monitoring 
developed achlorhydria and symptomatic dyspepsia with histological 
evidence of gastritis. The volunteers were followed up and 
improvement in gastric secretion and in histological gastritis was 
demonstrated after a period of 4 weeks (66). In the light of Warren 
and Marshall's work the biopsy specimens were re-examined and 
Helicobacter was identified (49). A similar phenomenon was reported 
by Gledhill in 1985 (67). In neither of the above reports was the 
electrode sterilised between subjects, the implication being that the 
organism was transmitted via the pH electrode.
In two reports investigators have ingested the organism and 
have developed gastritis. In 1985 Marshall ingested organisms 
while on Cimetidine (68). He subsequently developed a brief upper 
gastrointestinal upset and histological evidence of gastritis and 
Helicobacter infection. In 1987 Morris and Nicholson repeated the 
experiment, initially without Cimetidine, and did not develop 
gastritis. When they ingested the organisms with Cimetidine they too 
developed gastrointestinal symptoms and gastritis (69).
Further evidence to support a primary pathogenic role can be 
elicited from reports of eradication of the organism. Marshall 
reported resolution of gastritis in 8 out of 9 patients in whom 
H pylori was eradicated but not in patients in whom the organism 
persisted (70). McNulty demonstrated resolution of gastritis in 12 
of 13 patients in whom H pylori was eradicated compared to only 4 of 
32 in whom the organism was not eradicated (71). These findings have
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been confirmed by other authors (72,73).
Non-Ulcer Dyspepsia
The role of Helicobacter in non-ulcer dyspepsia is closely 
related to its role in Type B gastritis. As discussed above it is 
possible to subdivide these patients into two groups depending upon 
the presence or absence of histological gastritis. Wyatt studied 141 
patients with non-ulcer dyspepsia and identified 83 patients with 
histological gastritis (61). H pylori was found in 8956 of these 
patients and was not visualised in any of the remaining 58 patients 
with a histologically normal mucosa. These findings have been 
confirmed by other authors (74,75). It seems therefore, that 
Helicobacter is only of significance in patients with histological 
gastritis and not in those with a normal gastric mucosa.
Peptic Ulceration
Duodenal Ulcer
Following upon the reports of H pylori in relationship to 
gastritis Marshall and Warren reported a high prevalence of the 
organism in the gastric antrum of patients with duodenal ulceration 
(76). Since this time H pylori has been identified in 80-10056 of 
patients with duodenal ulceration (77,78,79). There has been some 
dissent, however, and neither Rollasson nor Girdwood could find an 
association between H pylori and peptic ulceration (80,81), and some 
authors have disputed its pathogenic role (82).
It was certainly recognised for many years that Type B 
gastritis was associated with duodenal ulceration. In 1967, prior to
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the current interest in H pylori, Schrager reported antral gastritis 
in 9 5% of patients with duodenal ulceration, although the 
significance of this finding was unclear (83).
Evidence to support a pathogenic role can be gained from 
reports on ulcer healing and relapse following eradication of H 
pylori. Much of the doubt surrounding this issue is based on the 
widely recognised success of H2 receptor antagonists in ulcer 
healing. These agents will heal more than 90$ of duodenal ulcers and 
and they have no demonstrable effect on Helicobacter colonisation 
(78,84). If, however, H2 antagonist therapy is stopped the relapse 
rate appears to be higher compared to patients in whom H pylori has 
been eradicated.
In 1987 Coghlan demonstrated an increased relapse at one year 
in patients who remained H pylori positive; 79$ compared to 17$ in H 
pylori negative patients (72), findings similar to those reported by 
Marshall (70). This is in keeping with pre H pylori evidence which 
demonstrated that colloidal bismuth, an agent with an antibacterial 
effect on H pylori, is associated with a lower rate of ulcer relapse 
than H2 receptor antagonists (85,86). Interpretation of this 
evidence, however, is open to debate. Colloidal bismuth has been 
shown to have a protective effect on the gastric mucosa by binding to 
glycoproteins and it may inhibit H+ back diffusion (87). It is 
therefore possible that colloidal bismuth exerts its anti-ulcer 
effect independently of its anti-bacterial properties. Similar 
criticisms have been levelled at antibiotics used to treat H pylori 
infection since some have been shown, experimentally, to have a 
protective effect on the gastroduodenal mucosa which is independent
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of their antibacterial action (82).
A further doubt exists as to why an organism found in the 
gastric antrum can give rise to duodenal ulceration, since the 
organism does not colonise the intestinal epithelium of the duodenum. 
Two possible explanations have been advanced to explain this.
High duodenal acidity, as seen in patients with duodenal ulcer 
(88), induces gastric metaplasia in the duodenum (89) and H pylori 
has been identified in these areas of metaplastic epithelium 
(90,91,92). It is therefore possible that areas of gastric 
metaplasia can become colonised by H pylori from organisms already 
present in the gastric antrum. Once colonisation has occurred the 
resultant high urease activity can induce H+ back diffusion and 
epithelial cell injury (52).
A second possible pathogenetic process relates to the effect of 
antral H pylori on gastrin secretion. Levy et al demonstrated 
elevated serum gastrin in duodenal ulcer patients colonised by H 
pylori compared with those who were H pylori negative (93). This led 
the authors to postulate that the alkaline environment due to local 
urease activity gives rise to an inappropriately high gastrin 
secretion and subsequent increase in gastric acid output.
It is also possible that both of these mechanisms work together 
to produce duodenal ulceration, and Helicobacter pylori is one factor 
in a the multifactorial aetiology of peptic ulcer disease.
Gastric Ulcer
The role of H pylori in the pathogenesis of gastric ulcer is 
less certain than its role in duodenal ulcer. The association is
42
less marked, with the organism being identified in between 53 and 77$ 
of patients with gastric ulceration (94,95). It is difficult to 
seperate gastric ulcer from gastritis since the two conditions tend 
to co-exist and it has been suggested that H pylori is more strongly 
associated with gastritis than with gastric ulceration (96).
Another possible explanation of the poor association may be the 
relationship of some gastric ulcers to exogenous influences such as 
non-steroidal anti-inflammatory agents, a factor which has not been 
taken into account in published reports.
Analysis of the evidence on healing fails to clarify the 
situation. Eui demonstrated improvement in gastritis and ulcer 
healing with coloidal bismuth, but no change in H pylori colonisation 
(95). More recently Humphreys demonstrated no association between H 
pylori eradication and ulcer healing (97). Tytgat confirmed that 
bismuth was no more effective in preventing the relapse of gastric 
ulceration than were H2 receptor antagonists (98), although other 
reports from the same author have demonstrated superior healing with 
bismuth (99,100).
Pathogenesis and Ultrastructural Changes
As discussed previously Helicobacter is only seen in 
relationship to gastric mucosa, being absent from areas of intestinal 
metaplasia and, when found in the duodenum, is identified only in 
areas of gastric metaplasia (101). The organism has been identified 
in normal body mucosa but always accompanied by histological 
gastritis in the antrum (49). With this exception the presence of 
Helicobacter is associated with gastritis in 97-100$ of cases
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( 60 , 61 ) .
Ultrastruetural studies performed by Goodwin and Marshall in 
1986 give strong support to a primary pathogenic role in gastritis 
(49). Electron microscopy studies have revealed characteristic 
changes in the gastric epithelium which resolve following eradication 
of the bacteria and which recur with reactivation of infection. The 
changes witnessed affected the mucus secreting cells and included 
ragged protrusions of the luminal cell surface, decrease or complete 
loss of surface microvilli and depletion of intracellular mucin 
granules with cellular oedema. The continuity of the epithelium was 
intact with no identifiable breaches in the mucosa. The changes were 
also witnessed in the superficial neck cells of the gastric pits but 
the glands themselves were normal. An infiltrate of neutrophils and 
lymphocytes was also identified.
The bacteria were seen to be on the cell surface and areas of 
adhesion were identified between the bacterial cell wall and the 
epithelial cell surface. The bacteria have been identified closely 
associated with the tight junction complexes between epithelial 
cells, allowing the bacteria access to the nutrients in this region. 
The organisms however, have not been identified in the lamina propria 
of normal individuals. Goodwin and Marshall did not observe 
intracellular organisms (49), although this has been observed as in 
uncommon occurrence by other authors (102,103). Goodwin & Marshall 
did, however, report phagocytosis by macrophages as a common 
occurrence (49).
The authors gave support to a pathogenic role by highlighting 
the similar ultrastruetural abnormalities identified in
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enteropathogenic E coli infection, including adherence pedicles, loss 
of microvilli and non-invasive bacteria restricted to the luminal 
surface (49).
Immune Response to H Pylori
Gastric colonisation with H pylori produces a typical non­
specific inflammatory infiltrate of histiocytes and neutrophils, 
containing remnants of bacteria, presumably the result of 
phagocytosis (49). Infection is also accompanied by an antibody 
response which can be detected serologically and locally in the 
gastric mucosa. Circulating antibodies to Helicobacter antigens have 
been detected by many authors (104,105,106).
The local antibody response has been investigated by Wyatt and 
Rathbone. They demonstrated IgM and IgA in gastric aspirates of 
patients colonised with Helicobacter (106). The same authors 
studied antibody distribution in the gastric mucosa by 
immunoperoxidase staining of IgG, IgA and IgM (61). They identified 
positive staining of bacteria with all 3 classes of immunoglobulin, 
and demonstrated IgG or IgM in 86$ of patients with Helicobacter 
associated active gastritis. They also demonstrated IgA which 
appeared to correlate less well with the activity of the gastritis, 
being demonstrated in all patients with active gastritis and in 60$ 
of those with inactive chronic gastritis. There was no positive 
staining in negative control specimens. The authors also noted that 
bacteria in the depths of the gastric pits were not coated with 
antibody.
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The precise nature of the antigens is unclear. They appear to 
react with various proteins on the outer membrane of the organism. An 
interesting report by Barer, in 1988, demonstrated abolition of the 
urease cytopathic effect by the addition of H pylori positive serum 
to H pylori urease, but not when added to urease from other sources, 
suggesting that some of the antibody is directed against the 
bacterial enzyme (107).Studies of antibody titres in therapeutic 
trials have demonstrated a fall in antibody titres following 
eradication of Helicobacter (105).
The above data once more lend support to the pathogenic role in 
gastritis with IgG and IgM secretion in the active phase and decrease 
in antibody titres following eradication of the organism and perhaps, 
in the future, serology may be a useful method of monitoring the 
response to treatment.
Cell Mediated Immunity
The cell mediated response to H pylori infection has been less 
extensively investigated. Yrios studied the effect of C jejuni on 
atbymic mice (108). Passive immunisation of athymic mice did not 
protect them from the effects of C jejuni when compared to euthymic 
mice, suggesting that an intact T cell response may be an important 
part of normal defence mechanisms. It is of course difficult to be 
sure of the significance of these findings in human infection with H 
pylori.
Recent work by Rathbone et al, as yet only published in 
abstract form, has studied T cell subsets in Helicobacter gastritis 
(109). They demonstrated a relative reduction in T suppressor/
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cytotoxic cells in both the epithelium and lamina propria of patients 
with H pylori associated gastritis, compared with normal antral 
biopsies. They also demonstrated an increase in T helper cells in 
the biopsies with an increased percentage expressing the CD7 marker, 
indicative of T cell blastogenesis, suggesting a primary immune 
response, presumably to H pylori
In the context of infection in transplant recipients the T cell
response is likely to be the most important factor. At present the 
current information makes it difficult to assess the importance of 
the T cell response in H pylori infection and the resulting increase 
in infection which might be expected in patients with a deficient T 
cell response.
Epidemiology of H Pylori
At present the only known source of H pylori is the human 
gastroduodenal mucosa and the organism has not been isolated from 
other sites (50). Similar organisms have been identified in the 
gastric mucosa of non-human primates although this is unlikely to be 
of importance in the general population.
Most information on the prevalence of H pylori in dyspeptic 
patients has come from endoscopic biopsies. This investigative
technique has obvious limitations in studying a healthy population
although one endoscopic study of healthy volunteers did demonstrate 
H pylori in 20JC (110). In population studies, however, alternative 
non-invasive methods have to be employed. Two such techniques are H 
pylori serology and urea breath testing.
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Graham studied asymptomatic patients using breath testing 
and found that the prevalence was age dependent rising from 5$ in 
those under 44 to 75$ in those over the age of 65 (111).
Serological studies have demonstrated a high prevalence of H 
pylori antibodies in up to 32$ and have confirmed an increase in 
prevalence with age rising from 10$ in those under 25 to 50$ in the 
over 55 age group (104,112). As discussed previously, however, this 
method does not necessarily detect active infection and may also 
cross react with antibody to several Campylobacter species and thus 
overestimate the prevalence of H pylori infection (111).
All of these studies suggest that the prevalence of H pylori is 
around 20-30$ but does show a marked increase with age. This is in 
keeping with the increased prevalence of gastritis which is known to 
occur with age (113). It is also interesting to look at the 
relevance of H pylori in an apparently asymptomatic population. 
Marshall, in an unselected group of blood donors found, that 50$ of 
those who were H pylori positive had symptomatic dyspepsia (114), 
suggesting that some of the healthy volunteers in the other reports 
may not be completely asymptomatic.
The mode of transmission of Helicobacter pylori is unclear and 
although there are well documented instances of transmission by 
gastric pH electrodes this is not relevant in the population at 
large.
It seems likely that person to person transmission is the most 
important source of infection. A high prevalence was demonstrated in 
upper gastrointestinal endoscopists (115), and several authors have 
demonstrated an increased prevalence in families of affected
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individuals and in patients in long stay psychiatric institutions 
(116,117). One study, as yet published only as an abstract, has 
demonstrated an increased prevalence of H pylori antibodies in people 
working with livestock (118). This is the only publication which 
has suggested transmission from an animal source, and the evidence at 
present favours person to person transmission, although the precise 
method of transmission is yet to be elucidated.
H Pylori in Immunocompromised Patients
There is little guidance in the literature on the importance of 
H pylori in immunocompromised patients. One case report describes 
gastritis in a patient with AIDS which responded to treatment with 
colloidal bismuth and amoxycillin (119). The clinical and 
histological features, however, were different from those in normal 
individuals. The patient had an acute severe illness with bacteria 
seen to invade the lamina propria, a feature not commonly identified 
in immunocompetent individuals. No information exists on H pylori 
infection in transplant recipients and the lack of data on cell 
mediated immunity to H pylori makes it difficult to predict the 
likely pattern of infection in these patients. One recent report has 
shown a very low prevalence of H pylori in haemodialysis patients 
(2.5?) although why this should be is unclear (90).
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CYTOMEGALOVIRUS
Introduction
Cytomegalovirus is a member of the herpes family of viruses. 
In common with other herpesviruses it is characterised by a cycle of 
primary infection, latency and reactivation. Infection with CMV 
produces enlargement of the cell (cytomegalia) which gives the virus 
its name, along with prominent intranuclear and, at a later stage, 
cytoplasmic inclusions.
Epidemiology
The prevalence of positive antibody titres to CMV, indicative 
of prior exposure to the virus, shows marked geographical and social 
variations. Data summarised by Krech shows titres of 40-80$ in 
Western countries rising to 100$ in the Far East and Africa (120). 
The peak incidence of infection occurs within the first two years of 
life, reaching a plateau by 50 years of age (120).
Transmission of the virus in the peri-natal period may be 
transplacental or via breast milk and in endemic areas respiratory 
transmission may be significant (121). In adults the routes of 
infection are less clear although sexual transmission is thought to 
be important (122). Other modes of transmission such as blood 
transfusion and allograft transplantation are well established, 
although of minor importance in the general population.
50
Clinical Features
Primary infection in healthy adults is most commonly 
asymptomatic. When symptoms do occur they usually take the form of a 
mild mononucleosis type of illness with lymphadenopathy, myalgia, a 
mild disturbance of hepatic transaminases and atypical lymphocytosis 
(123,124). The disease is usually self limiting, lasting two to 
three weeks. During the acute infective episode virus can be readily 
isolated from the throat and urine.
Viral Latency
Once the acute infection has resolved the virus establishes 
latency within the host cells. Identification of the sites of latency 
has been difficult although the virus has been demonstrated in renal 
tubular epithelium and salivary glands (125). The latent virus has 
also been identified in lymphocytes, mainly the T helper subset 
(126). This is in keeping with the intermittent excretion of virus 
in urine and saliva and transmission by blood transfusion (127).
Reactivation of latent virus is of little importance in healthy 
individuals, although can be a source of considerable morbidity in 
immunosuppressed and immunocompromised patients.
Cytomegalovirus in Transplant Patients
Primary infection with CMV and reactivation of latent virus can 
give rise to a much more severe illness in transplant recipients than 
is seen in the general population. Cytomegalovirus infection was
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recognised as a complication in the early days of renal 
transplantation (128,129). The prevalence of infection varies with 
the definition but can be in excess of 70% based on seroconversion or 
a rise in antibody titres (130,131) although many of these infections 
are subclinical.
Cytomegalovirus has also been implicated as a factor in 
allograft rejection (132), with increased expression of class II MHC 
antigens in the allograft.This may be mediated by gamma interferon 
released as a result of CMV infection (133).
In the past infection was classed as reactivation if it 
occurred in a seropositive recipient and primary infection when it 
occurred in a seronegative recipient. Epidemiological evidence 
demonstrated an increased risk of infection in recipients of an organ 
from a seropositive donor suggesting that the donor organ was the 
major source of virus (13^,135). This has been confirmed by 
demonstration of identical viral strains in matched recipient pairs 
(136). Further work with matched recipient pairs in seropositive 
recipients has suggested that the majority of infections are due to 
viral strains from the donor organ and are therefore primary 
infections and not reactivation of endogenous virus (137,138).
Cytomegalovirus In the gastrointestinal tract
In rare instances CMV has been described associated with 
ulceration and bleeding in the gastrointestinal tract in 
immunocompetent individuals. These amount to a few case reports,
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usually in patients following multiple trauma (139,140,141). There 
have, however, been many more such reports in transplant recipients 
and in patients who are immunosuppressed or immunodeficient for other 
reasons.
Transplant Recipients
In the 1970’s reports began to appear in the literature linking 
CMV to ulceration and haemorrhage in the upper GI tract. Millard in 
1973 reported 3 cases of cytomegalic inclusions in the presence of 
erosive gastritis (142), and Diethelm in 1976 reported a case of 
haemorrhagic gastritis, again with typical cytomegalic inclusions
(143). More comprehensive reviews were reported by Franzin and by 
Cohen in 1981 and 1985 respectively (8,11).
The first paper reported a retrospective analysis of 20 
asymptomatic renal transplant recipients between one and 24 months 
after transplantation. The authors identified cytomegalic inclusions 
in 9 of the 20. In 8 of these patients the duodenum was involved and 
duodenitis was identified endoscopically in 6, of whom only 2 had 
symptomatic dyspepsia. Only 2 of the 9 patients had similar 
histological changes in the gastric mucosa, although 7 patients had 
endoscopic evidence of gastritis. The study also identified a 
significant association between primary infection and cytomegalic 
inclusions in the gastroduodenal mucosa, suggesting that primary 
infection of a seronegative patient carried a greater risk of 
infection in the upper GI tract (8).
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Cohen et al reported on 11 surgical resections or autopsy 
specimens from renal transplant recipients. They found cytomegalic 
inclusions in 5 of 8 patients with peptic ulcers. All of the 
patients had suffered a GI bleed within the first year of 
transplantaion and 3 of the patients with CMV inclusions died as a 
result of GI haemorrhage. Serology was not available on the patients 
in this study and no comment could be made on the association with
primary or secondary infection (11).
A more recent paper by Alexander et al reported results of a
prospective study in patients before and after liver transplantation
(144). The authors studied endoscopic biopsies histologically and by 
viral culture and also looked at smears of mucosal brushings. All 
patients were seropositive and infection was presumed to be re­
activation. Cytomegalovirus was isolated in 33$ of patients 
following transplantation, compared with 2$ prior to transplantation. 
Interestingly inclusions were identified in only 25$ of patients with 
positive cultures suggesting that the reports by Franzin and Cohen 
may have significantly underestimated the prevalence of infection. 
Alexander also found an association between cytomegalic inclusions 
and symptomatic dyspepsia.
Acquired Immune Deficiency Syndrome
The large and expanding population of patients with AIDS are 
susceptible to opportunistic infection and recent reports from the 
United States have identified CMV as a possible pathogen.
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Inclusions have been identified in the stomach, gallbladder, small 
bowel and colon often with fatal results (145,146,147,148).
Mobley reported an interesting finding of multiple polypoidal 
lesions in the small bowel due to CMV associated submucosal lymphoid 
hyperplasia (149).
Clearly the severity and magnitude of the disease in patients 
with AIDS is much greater than in transplant recipients. This may be 
due to a more profound immunosuppression or may be due to the high 
CMV seropositivity of individuals in the high risk groups for the 
development of AIDS.
Pathogenesis
In the GI tract cytomegalic inclusions have been identified in 
surface and in glandular epithelium, in fibroblasts, smooth muscle 
cells, and vascular endothelium (8,11,143). Hinnant reported that 
only 10$ of the infected cells were epithelial and the remainder were 
mesenchymal, including smooth muscle and vascular endothelial cells 
(147). This feature was also observed by Cohen who noted striking 
inclusions in vascular endothelium in ulcer bases, with evidence of 
thrombosis and focal epithelial necrosis (11). This is in keeping 
with reports of endothelial infection in other sites such as the 
kidney and retina.
It is clear that either epithelial infection or small vessel 
thrombosis and ischaemia could result in a breach of the 
gastroduodenal mucosa, subjecting the underlying tissue to acid
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pepsin digestion.
Conclusions
Cytomegalovirus is a well established pathogen in transplant 
recipients and evidence from case reports and small series have 
suggested an aetiological role in the upper gastrointestinal 
complications of transplantation. It is, however, difficult to prove 
a causal role in view of the many other aetiological variables and in 
view of the lack of information on gastrointestinal CMV in the 
general population. Information must be collected prospectively with 
a group of control patients, along with information on donor and 
recipient serological status, concurrent drug administration and 
detailed histological assessment of the distribution of infected 
cells.
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HERPES SIMPLEX VIRUS
Herpes simplex virus (HSV) is the major virus of the herpes 
group and, as with CMV, is characterised by infection, latency and 
reactivation. Unlike CMV however, all of these events occur 
frequently in the general population. The virus can be divided 
serologically into two distinct types, termed HSV1 and HSV2 (150). 
More recently restriction endonuclease analysis has identified 
different strains within these two subtypes (151,152).
Infection and Epidemiology
The two commonest forms of herpes simplex infection are oral 
and genital, producing the characteristic vesicular lesion on the 
skin and mucous membranes. The lesions are usually self limiting and 
resolve after two to three weeks (153). More severe forms of 
infection in healthy adults include aseptic meningitis and 
encephalitis, the latter associated with a mortality of 70$ and a 
high incidence of neurological deficit in survivors (154).
The importance of each subtype of HSV varies with the site of 
involvement. HSV1 is responsible for over 90$ of oral infections and 
HSV2 for a similar proportion of genital infection. In other sites 
the distinction is less obvious (155).
Prior exposure to HSV is widespread in the community as judged 
by serological studies. The prevalence of antibody to HSV1 tends to 
be falling and in developed countries is reported at around 40$ 
(156). Transmission is by close personal contact and peak incidence 
of infection occurs in the second year of life.
The distribution and transmission of HSV2 is quite different.
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Antibodies are not commonly detected until after puberty (157). 
Transmission is primarily sexual and there has been a progressive 
increase in HSV 2 infection over the past 20, years presumably 
related to changing sexual practices (158).
Latency and Reactivation
The mechanisms of the establishment of latency and reactivation 
are unclear despite early recognition of the phenomenon and its 
importance in transmision of the disease. Primary infection leads to 
migration of the virus along somatic or autonomic axons, establishing 
latency in neural ganglia. Following reactivation viable virus is 
shed from the secondary lesions (157). It is likely that most people 
who have been exposed will harbour latent virus, although only a 
minority will ever develop secondary infection (159,160). During 
latency it is assumed that the viral genome is innactive, and no 
virus derived peptides have been identified in infected ganglia 
( 161).
The triggering factors for reactivation include nerve trauma, 
ultraviolet light exposure and intercurrent illnesses, although the 
precise triggering mechanisms remain unknown (153).
Herpes Simplex in Transplant Recipients
Early in the history of transplantation an increase in HSV 
infection was recognised in the post-transplant period. In 1973 
Lopez reported HSV in 21$ of renal transplant recipients (162). Most 
studies have reported infection with HSV in between 45$ and 55$ of 
kidney, heart and liver recipients (128,131,163). In these studies
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infection is usually defined by positive culture and the prevalence 
of clinical infection is generally lower at around 20-50$ (131,164).
The distribution of infective lesions is primarily 
nasopharyngeal with very few genital infections, and the disease is 
usually mild with no adverse effect on patient or graft survival 
(165). In rare instances disseminated disease has been reported 
producing encephalitis, hepatitis, pneumonitis and widespread 
cutaneous lesions (166,167,168,169). The clinical consequences of 
HSV infection in the transplant population, however, are much less 
than the consequences of CMV infection.
In the majority of transplant recipients infection is thought 
to be due to reactivation of latent virus with viral excretion 
occurring in up to 85$ of seropositive recipients (170). In rare 
instances infection has been reported in seronegative recipients and 
it is possible that the virus can be acquired from the donor organ 
(171,172).
Herpes Simplex in the GI Tract
Herpes simplex infection in the GI tract is unusual in 
otherwise healthy individuals, although herpetic eosophagitis has 
been reported in such patients (173,174). Herpetic oesophagitis is, 
however, a well recognised problem in immunodeficient patients (175). 
The infection may spread from oropharyngeal infection or via the 
vagus nerve from latent virus in the vagal nucleus (176). Clinical 
features of the infection include odynophagia and dysphagia, and 
endoscopy may reveal multiple shallow ulcers (176).
If spread via vagal fibres is indeed a pathway for oesophageal
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infection it would seem likely that spread to involve other parts of 
the upper GI tract would also occur. It was certainly suggested 
almost thirty years ago that HSV may be an aetiological agent in 
peptic ulceration (177). Herpes simplex has been identified in vagal 
ganglia, and patients with duodenal ulceration have been demonstrated 
to have higher HSV antibody titres than normal control subjects. In 
clinical practice, however, this does not appear to be the case. 
Buss et al found only one case of HSV associated gastritis in 50 
patients with oesopahagitis (175) and there are only a few reports of 
infection affecting the liver and pancreas (176,178). One recent 
study examined the effects of acyclovir in preventing duodenal ulcer 
relapse (179). The rationale behind this study was that acyclovir is 
known to reduce the frequency of reactivation of Herpes simplex, and 
it was hoped that the drug would reduce the frequency of duodenal 
ulcer relapse. This, however, did not occur and the authors concluded 
that Herpes simplex was not implicated in the pathogenesis of peptic 
ulceration. It would, however, be difficult to draw such a definite 
conclusion from such an indirect study method.
Large bowel infection appears to occur more commonly and 
anorectal infection is widely recognised in homosexual men (180,181). 
More widespread colonic involvement has also been seen in 
immunocompromised patients including transplant recipients (182).
With the exception of oeosphagitis HSV has not been reported as 
a major pathogen in the upper GI tract. The histological diagnosis 
however is difficult and neither immunohistochemistry nor in situ 
hybridization techniques have been used to determine the relationship 
of the virus to ulceration, gastritis or duodenitis, lesions not 
normally associated with herpetic infection.
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IMMUNOSUPPRESSION IN TRANSPLANT RECIPIENTS
In the early days of renal transplantation it became obvious 
that, although an operation could be technically successful, long­
term graft function was not achieved. As early as 1914 it was 
recognised that pharmaceutical methods of controlling rejection were 
necessary. This remained a problem until the mid 1950*3 when modest 
success was achieved by using corticosteroids. Renal 
transplantation, however, was not widely performed and did not become 
so until the more widespread use of immunosuppression became a 
practical possibility.
In the late 1950’s whole body irradiation was used along with 
cytotoxic agents, particularly 6 mercaptopurine. By 1962 a 
derivative of 6MP, BW 57-322, was used by Caine and was demonstrated 
to confer greater graft survival and was associated with less 
toxicity than 6MP (183). This compound became known as azathioprine 
and was to become the mainstay of immunosuppression for almost 20 
years. By 1963 azathioprine was used routinely with prednisolone and 
allowed the expansion of renal transplantation with long-term graft 
survival (184).
This combination, however, was not without complications. 
Infection was a common and almost inevitable problem, occurring in up 
to 80£ of patients (185). Azathioprine produced a widespread immuno 
and myelosuppression with inhibition of humoral and cell mediated 
immunity and the inflammatory response, predisposing the patients to 
a wide range of bacterial, viral and fungal infection (186).
Around 10 years ago 3 important advances were made in the 
immunological management of transplant recipients. These were the
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identification of the HLA DR antigen, allowing better tissue 
matching, a realisation that lower doses of corticosteroids could be 
used successfully, and the introduction of cyclosporine into clinical 
practice. As discussed in Chapter 1 the prevalence of GI 
complications appeared to decrease over this time period and was 
presumed to be due to decreasing corticosteroid dose (9). The other 
two factors, however, are also likely to be important because of 
their effect on viral and bacterial infection in the upper GI tract.
Cyclosporine
Unlike azathioprine cyclosporine exerts a much more specific 
effect on the immune system and is neither cytotoxic nor 
myelosuppressive. Cyclosporine inhibits the production of 
interleukin 2 (IL-2) and inhibits the responsiveness of cytotoxic T 
cells to IL-2. An indirect effect of its action on T cell 
proliferation is to inhibit the production of T cell lymphokines, 
thereby suppressing macrophage function. A further consequence of 
this is a decreased production of macrophage derived IL-1 and 
subsequent suppression of T helper lymphocyte activation. T 
suppressor cells,however,are unaffected. The net result, therefore, 
is an inhibition of cytotoxic and helper T cells and macrophages with 
sparing of suppressor T cell function (187). There is also evidence 
to suggest that there may be a mild inhibitory effect on humoral 
immunity (187), but less than experienced with azathioprine. The 
greater specificity of cyclosporine, therefore, results in a 
decreased risk of bacterial and fungal infections, although viral 
infections which are primarily T cell mediated are unaffected (187).
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CHAPTER 3
METHODS
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SUMMARY
The study was performed on renal transplant recipients 
obtaining endoscopic biopsies of the gastroduodenal mucosa. The 
biopsy material was then split, half being fixed in formalin and half 
frozen in liquid nitrogen. A retrospective group of normal gastric 
and duodenal biopsies was obtained, age and sex matched and, in 
addition, a prospective age and sex matched group of patients was 
utilised to obtain fresh tissue which was subsequently frozen. The 
formalin fixed tissue was analysed by immunohistochemistry using 
anti-CMV and anti-HSV antibody. The material was also examined for 
the presence of Helicobacter pylori and assessed for the grade of 
gastritis and duodenitis. The frozen tissue was used for the study 
of T cell subsets.
INTRODUCTIOH
The clinical methods used are straightforward and will be dealt 
with in detail later in this chapter, along with details of the 
laboratory methods. This introduction will, therefore, outline the 
background to the laboratory methods.
Immunohi sto chemi stry
Immunohistochemistry was utilised in this study for the 
detection of CMV and HSV and for analysis of mucosal T lymphocyte 
subsets. This is a technique which allows the identification of a 
tissue consituent by means of a specific antigen - antibody reaction 
tagged by a visible label (191). The technique was first described 
in 1941 (192) but it has been the wide availability and ease of
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production of specific monoclonal antibodies which has prompted a 
rapid growth in the applications of this method over the past 10 
years.
As described by Coons (192) the label used to visualise 
antibody localisation was Fluoresceine which necessitated viewing 
under ultraviolet light. It is now, however, possible to use 
labelling techniques which can be viewed by standard light 
microscopy, the common labels relying on enzymes such as peroxidase 
or alkaline phosphatase to produce a colour change when reacted with 
the appropriate substrate.
Initial descriptions of the technique utilised a single or 
direct method, where the primary antibody carried the label (Fig 3). 
A development of this technique has been the use of an indirect 
method whereby the primary antibody will bind to the appropriate 
antigen and the secondary antibody, carrying the label, will then 
bind to the primary antibody (Fig 4). This technique has two major 
advantages over the direct method.
Firstly a wide range of primary antibodies can be visualised by 
using a single labelled secondary antibody and, secondly, the 
staining can be amplified since the primary antibody will bind 
several molecules of labelled secondary antibody (191).
Further developments have aimed to increase the sensitivity of 
the staining by improving the linkage technique. One such method is 
the peroxidase anti peroxidase technique which utilises a third layer 
antibody conjugated to peroxidase (Fig 5). The most recent 
developement and the one used in this study utilises an avidin, 
biotin linkage.
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FIG 3. Direct antibody technique showing labelled antibody bocnd to tissue antigens.
FIG.4 Indirect antibody technique illustrating labelled secondary anttoody bourd to the 
primary antibody.
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FIG.5 Peroxidase antiperoxidase technique. The third layer consists of a 
peroxidase antibody complex which binds to the secondary antibody.
Avidin is a glycoprotein of egg white origin which will bind to 
four molecules of the vitamin biotin. In this technique the 
secondary antibody is conjugated with biotin and the third layer 
consists of an avidin, biotin peroxidase complex which will bind to 
the antibody biotin conjugate. This amplifies the staining intensity 
since each avidin biotin complex will contain three molecules of 
peroxidase and each secondary antibody can bind several molecules of 
biotin (Fig 6). The technique has been demonstrated to be superior 
to standard indirect or peroxidase anti peroxidase methods (193).
The major disadvantages of immunohistochemical techniques are 
failure of the antibody to bind to the appropriate antigen producing 
a false negative reaction and inappropriate background staining 
producing a false positive reaction.
The commonest reason for a false negative reaction is 
destruction of the antigen by the fixation process (19*0. This 
varies with each antigen and antibody. In our work anti HSV and anti 
CMV can readily be used in fixed tissue (195,196) whereas the 
monoclonal antibodies used for T cell subset analysis must be used on 
unfixed tissue. In some instances binding can be increased by 
enzymatic digestion with trypsin or pronase prior to application of 
the primary antibody (197)
False positive reactions can be caused by endogenous label 
within the tisue specimen. This occurs commonly with peroxidase but 
can be overcome by pretreating with hydrogen peroxide (191)•
In practice most false positive reactions occur because of non­
specific antibody binding. The major step to overcoming this problem 
is the use of affinity purified monoclonal antibody (191). There
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FIG 6  Avidin Biotin Technique.
will still be, however, non-specific staining due to antibody 
adhering electrostatically to collagen. The simplest method of 
overcoming this problem is to block these sites prior to application 
of the primary antibody with, for example, bovine serum albumin.
Based on the reasons given above the method chosen by us for 
this analysis is a double antibody peroxidase avidin biotin 
technique on fixed tissue for CMV and HSV and a double antibody 
alkaline phosphatase method on unfixed tissue for T cell subsets. 
Details of the staining techniques are at the end of this chapter.
Helicobacter Pylori
The presence of Helicobacter pylori was assessed in both 
gastric and duodenal biopsies. It is well recognised that the 
distribution of H pylori is patchy in the gastroduodenal mucosa (188) 
and, therefore, multiple biopsies were obtained. The organism was 
identified on histological sections and using a proprietary urease 
slide test.
Urease Slide Test
This is a rapid diagnostic test for Helicobacter pylori, 
developed by Marshall (60). The principle involves hydrolysis of 
urea by urease to ammonia. The slide test consists of a gel pellet 
containing urea and phenol red, buffered to an acid pH. At a pH 
level of less than 6.0 phenol red exists in a yellow form. In the 
presence of Helicobacter pylori the production of ammonia will raise 
the pH and induce a colour change from yellow to red (Fig 7)» The 
proprietory slide test used in this study (CLOtest, Delta West Ltd,
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Figure 7s Urease slide tests showing a negative result (above) and 
positive result (below).
Bentley, Western Australia) is the same as that evaluated by Marshall 
who found a good correlation between CLOtest, culture and 
histological findings (60). Marshall analysed the slides for a 
colour change at 20 minutes, 2 hours and 24 hours, and found no false 
positive CLOtests if a colour change up to 24 hours was included. In 
the same study only one false positive was identified out of 79 
patients.
Histological Examination
The demonstration of H pylori can be achieved on routine H&E 
sections (Fig 8), but is more reliably detected by the utilisation of 
special stains. The original papers on the subject favoured the 
Warthin starry silver stain (49). As with other silver stains, 
however, this is a complex procedure to perform and has been reported 
to give variable results (189,190). Our laboratory has used a cresyl 
fast violet stain for several years with results comparable to those 
for silver stains (190). One pitfall of the cresyl violet stain is 
uptake by intestinal mucus, however, once recognised, confusion with 
Helicobacter is easily avoided (Fig 9).
CLINICAL METHODS
Transplant Recipients
All renal transplant recipients of eighteen years and over were 
invited to attend for upper gastrointestinal endoscopy. The patients 
were approached directly or by telephone backed up by an explanatory 
letter. Full informed consent was obtained and ethical committee 
approval had been obtained. Endoscopy was timed to take place at
68
Figure 8: H & E section of the gastric mucosa. H pylori can be
seen faintly in the mucus of the gastric pit. (x40)
Figure 9: Section of gastric mucosa stained with cresyl fast
violet (Figure 8). H pylori can be identified clearly 
as small rodlike structures on the luminal surface.(x40)
between 2 End 4 months after transplantation. Patients who had 
developed complications in the allograft or who, for other reasons, 
were deemed too ill to participate were excluded. Prior to endoscopy 
a questionaire was completed obtaining details of dyspeptic symptoms 
both before and after transplantation, along with details of current 
medication. The questionnaire was also completed for those patients
who declined to participate in the study.
CMV status was assessed by obtaining venous blood for antibody 
titres prior to endoscopy. The pre-transplant CMV status of the 
donor and recipient were available for most of the patients as part 
of the routine management.
Endoscopy was performed with an Olympus 1T10 end viewing upper 
GI endoscope. The patients were sedated with 10mg of Diazemuls 
intravenously and were also given 20mg of Hyoscine butylbromide to 
decrease peristaltic activity during the examination. The upper 
gastrointestinal tract was examined as far as the second part of the 
duodenum. All abnormal lesions were biopsied and random biopies 
were obtained from the gastric antrum and from the first part of the 
duodenum where these were normal. At least six specimens were 
obtained from each site. All endoscopic findings were recorded on the 
patient proforma.
Tmnmno.cmDDressive Regime
All of the patients were on haemodialysis or peritoneal 
dialysis prior to transplantation. Allografts were matched for ABO 
and for HLA DR. Where possible a match was also obtained for HLA A
and HLA B although this was variable. The patients were commenced
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on cyclosporine I6mg/kg eight hours before transplantation and were 
given 1G of methylprednisolone intraoperatively. In the postoperative 
period immunosuppresion was continued with cyclosporine and 
prednisolone, and information on serum cyclosporine and prednisolone 
dosage was available. It is also the practice of the unit to use 
azathioprine and OKT 3 in some instances but only three of the 
patients in the study group received 0KT3 and none received 
azathioprine.
Control Tissue
Two groups of control subjects were obtained. The first group 
consisted of retrospective age and sex matched subjects, comprising 
normal gastric and duodenal biopsies drawn from formalin fixed 
paraffin mounted tissue in the Department of Pathology. This tissue 
was used for analysis of CMV and HSV. The other control tissue was 
obtained prospectively from patients undergoing routine diagnostic 
endoscopy. The examination was performed as described above and six 
random biopsies were obtained from both the gastric antrum and 
duodenum and were frozen in liquid nitrogen. The patients were age 
and sex matched and were matched for Helicobacter status.
Processing of Biopsy Specimens
In the early part of the study period all biopsy specimens were 
fixed in formalin. These were suitable for analysis of CMV, HSV, 
Helicobacter pylori and for grading of gastric and duodenal 
inflammatory changes. In the latter part of the study the specimens 
were split, half being fixed in formalin and half frozen immediately
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in liquid nitrogen and stored at -70°C and subsequently used for 
analysis of T cell subsets. In the second control group all 
specimens were frozen and stored for T cell subset analysis and in 
both the transplant recipients and the second control group an 
additional antral biopsy was used for urease slide test analysis.
Urease Slide Test
A proprietory slide test was utilised (Clotest, Delta West Ltd, 
Bentley, Western Australia). A colour change up to 24 hours was 
deemed to be positive (60).
Antibody Titres
CMV status was assessed in the study group by complement 
fixation test and by IgM titres.
Interpretation of Histological Sections
All histological sections were examined independently by myself 
and by Dr M Burgoyne. The sections were identified by number only 
and the examiners were blind to the clinical information and to the 
results of the other histological sections for each patient. Where 
there was a difference of opinion the sections were reviewed and a 
consensus was reached. Analysis was for the presence of positive 
staining for Cytomegalovirus and Herpes simplex by 
immunohistochemistry and positive staining for Helicobacter pylori. 
In addition to the presence of staining the distribution within the 
section was also noted. Gastritis and duodenitis were scored as 
described below.
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Mucosal T Lymphocyte Subsets
Mucosal T lymphocyte subsets were assessed on frozen tissue 
from the study group and from control subjects. The estimation was 
performed on gastric and duodenal biopsies by counting the number of 
Leu3 and Leu2 positive cells. The counting was performed manually by 
two assessors independently for the full area of the biopsy. The 
area of the biopsy was then measured on an Optomax image analyser and 
the total T cell counts were expressed per mm^. The ratio of Leu3 to 
Leu2 was then calculated.
Histological Assessment of Gastric and Duodenal Mucosa
Gastric Mucosa
The system of scoring for gastritis, atrophy and intestinal 
metaplasia was used as described by Watt et al (201). Each section 
was scored from 0 to 5 as summarised below (Figs 10-12).
Gastritis
1) Minimal infiltrate of inflammatory cells in the superficial
layer of the lamina propria.
3) Heavy infiltrate of inflammatory cells throughout the lamina
propria.
5) Heavy infiltrate of acute and chronic inflammatory cells
(active chronic superficial gastritis).
Atrophy
1) Minimal loss of specialised glands.
3) Loss of half of the specialised glands.
5) Almost complete loss of specialised glands.
Metaplasia
1) One or two gastric pits affected.
3) Half of the gastric pits affected.
5) Almost all of the gastric pits affected.
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Figure 10: H & E section of normal gastric mucosa.(x25)
Figure 11: H & E section of moderate gastritis (Grade 3).(x25)
Figure 12: H & E section of severe gastritis (Grade 5) with
intestinal metaplasia in the lower left of the 
section.(x25)
Duodenal Mucosa
Inflammatory changfis in ths duodenal mucosa were graded 
according to the criteria of Whitehead et al (202). The density of 
the inflammatory infiltrate and epithelial evidence of neutrophils 
and metaplasia are noted separately (Figs 13,14).
Duodenitis
0) Normal
1) Superficial epithelium normal, but increased cellularity of the 
lamina propria.
2) Changes as above, along with abnormality of the surface
epithelium such as flattening of the cell, and nuclear
hyperchromasia.
3) Erosion of the surface epithelium.
A score of 2 or 3 was taken to be consistent with significant 
duodenitis.
Staining Techniques
Cresvl Fast Violet 
Reagents
1) 0.255 Cresyl violet acetate.
2) Cresyl violet differentiator; 9556 alcohol - 90ml; chloroform -
10ml, acetic acid - 3 drops.
Technique
1) Remove paraffin in Xylene for 10 minutes.
2) Remove Xylene with absolute alcohol.
3) Rehydrate by immersion in graded alcohol.
4) Stain with 0.256 cresyl violet acetate for 5 minutes.
5) Rinse in water.
6) Rinse in 9556 alcohol.
7) Differentiate in cresyl violet differentiator.
8) Rinse in absolute alcohol.
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/Figure 13: H & E section of normal duodenum. (x25)
XFigure 14: H & E section of duodenitis (Grade 2).(x25)
9) Clear section and mount.
This method will stain nuclei violet, the cytoplasm will be 
colourless and Helicobacter pylori will show as a deep blue 
violet.
Immunohi s t o chemi stry
Reagents
1) Blocker - 2% Bovine serum albumin.
2) Enzyme substrate - CMV, HSV- Diaminobenzidine 0.05?.
LEU2,LEU3-Levamisoloe 2.5mg, Fast red violet 5mg, 20ml veronal 
acetate/HC1 buffer pH 9.2.
4) Primary Antibody
a) CMV
Monoclonal mouse anti CMV, clone CCH2. (DAKO Ltd,16 Manor 
Courtyard, Hughenden Ave, High Wycombe, Bucks HP 13 5RE).
b) HSV
Rabbit anti Herpes Simplex Virus I & II H243A. (Immunotag, 
Lipshaw, 7446 Central Ave, Detroit, Michigan 48210).
c) Leu2
Anti Leu2 (Becton Dickenson Ltd, Cowely, Oxfordshire).
d) Leu3
Anti Leu3 (Becton Dickenson Ltd).
5) Secondary antibody
CMV Sheep anti mouse biotin peroxidase conjugate (Amersham 
International pic, Amersham UK).
HSV Donkey anti rabbit biotin peroxidase conjugate (Amersham 
International).
LEU2, LEU3 Rabbit anti mouse alkaline phosphatase conjugate 
(Becton Dickenson Ltd)
6) Streptavidin, bio tin, peroxidase complex (Amersham 
International).
Avidin Biotin Technique
1) Remove paraffin in xylene for 10 minutes.
2) Remove xylene with absolute alcohol.
3) Rehydrate by immersion in graded alcohol.
*0 Remove endogenous peroxidase by immersion in Methanol and
Hydrogen Peroxide for 30 minutes (60 parts : 1 part).
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5) Wash in water.
6) Treat sections with blocker for 10 minutes.
7) Remove blocker and treat sections with diluted antibody, at 4°C
for 16 hours.
8) Wash sections with phosphate buffered saline for 30 minutes.
9) Apply secondary antibody at room temperature for 30 minutes.
10) Wash with phosphate buffered saline for 30 minutes.
11) Treat with ABP for 30 minutes at room temperature.
12) Wash with phosphate buffered saline for 30 minutes.
13) Treat with diaminobenzidine for 5 minutes.
14) Wash in water, stain nuclei with eosin, clear and mount.
Alkaline Phosphatase Technique
1) Fix in acetone for 10 minutes.
2) Treat with blocker for 10 minutes.
3) Incubate with primary antibody for one hour at room temerature.
4) Wash with tris buffered saline.
5) Apply second layer antibody for one hour.
6) Wash with tris buffered saline.
7) Add enzyme substrate for 10 minutes.
8) Wash with water and fix in buffered formalin for 10 minutes.
9) Counterstain with haematoxylin.
Statistical Analysis
Statistical analysis was by the Chi squared test with a Yates 
correction or the Fishers exact test for 2 by 2 contingency tables 
and by the two sample t test and Mann-Whitney U test for parametric 
and non parametric data respectively.
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Patient Recruitment
The study was performed between April 1988 and May 1989. All 
patients who had undergone renal transplantation between February 
1988 and March 1989 were eligible for inclusion, producing a 
potential study group of 69 patients. Prior to invitation the 
patients* clinical history was reviewed and decisions taken to 
exclude patients on clinical grounds. In total 18 patients were 
excluded for the reasons outlined in Table 1.
Fifty one patients were therefore invited to attend. Seventeen 
patients declined to participate in the study, leaving 34 patients 
who underwent endoscopy. One endoscopic examination was a technical 
failure. Thirty three patients completed the study protocol and 
comprise the study group in this thesis.
Non-Attenders
Information was obtained on those patients who declined the 
invitation to participate. This included information on H2 receptor 
antagonist (H2RA) use, dyspeptic symptoms, renal function, serum 
cyclosporine and prednisolone dosage. This information is summarised 
in Table 2.
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TABLE 1
DETAILS OF PATIENTS EXCLUDED
Moved or lived outwith area 6
Allograft failure 4
Patient death 3
Major rejection episodes 2
Other medical complications 2
Under age 1
Total 18
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Study Group
The study group comprises 33 patients. The data on dyspeptic 
symptoms, H2RA use, renal function, serum cyclosporine and 
prednisolone dosage are shown in Table 2 for comparison with the non- 
attenders. In addition the study group was divided into symptomatic 
and asymptomatic and the data for both of these groups is illustrated 
in Table 3. Symptoms refer to post transplantation.
Comparison of Groups
There were no significant differences between the study group 
and the non-attenders in terms of symptoms, H2RA use, renal function 
cyclosporine levels and prednisolone dose. Comparison of the two 
subdivisions of the study group revealed a significantly higher 
prevalence of H2RA use in the symptomatic group. There was a 
tendency for the symptomatic group to be older to have higher serum 
levels of urea, creatinine, cyclosporine and higher prednisolone 
dose, but these differences did not attain statistical significance.
Analysis of Symptoms and H2RA Use
Twenty of the patients attending for endoscopy (60%) had 
symptoms referrable to the upper GI tract compared to 8 (47%) of 
those who did not attend.
In the study group there was a non significant increase in 
symptoms following transplantation, although this change was not seen 
in those who did not participate in the study. Details of the
symptoms in both groups are illustrated in Table 4.
Eight of the non-attenders (47%) were on ranitidine at the time
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of the study, compared with 15 patients (*5?) la the study group_
This comprised 12 in the symptomatic group (60?) and 3 in the 
asymptomatic group (23?) (p=0.02). In the study group pnly $ ^  ^
15 patients (33?) experienced an improvement in their symptoms 
following administration of H2 receptor antagonists.
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TABLE 2
COMPARISON OF NON-ATTENDERS AND STUDY GROUP
Non-attenders Study Group
(N = 17) (N = 33)
Dyspepsia 8 (47*) 20 (6055)
H2RA 7 (41*) 15 (45*)
Mean urea (mmol/1) 11.27 10.7
Mean creatinine (umol/1) 189 166
Mean serum Cyclosporine 161 129
(nmol/1)
Mean prednisolone 17
dose (mg)
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TABLE 3
COMPARISON OF SYMPTOMATIC AND ASYMPTOMATIC PATIENTS
SYMPTOMATIC ASYMPTOMATIC
(N=20) (N=13)
Mean age 41.9 38.2
H2RA 12 3*
Mean urea (mmol/1) 11.4 9.8
Mean creatinine (umol/1) 179 197
Mean serum Cyclosporine 
(nmol/l)
134 121
Mean prednisolone dose(mg) 20.1 15.
* p=0.02 (Fishers exact test)
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TABLE 4
DETAILS OF PRE-TRANSPLANT AND POST-TRANSPLANT 
SYMPTOMS IN BOTH GROUPS
Study Group Non-attenders
(N=33) (N=17)
Symptoms Pre-Tx Post-Tx Pre-Tx Post-Tx
Heartburn 8 15
Dyspepsia 7 12
Nausea
Anorexia
Total Patients 10(30$) 20(60$) 7(41$) 8(47$)
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Endoscopic Findings
The endoscopic findings are summarised in Table 5. The 
inflamamtory mucosal changes refer to endoscopic appearances only. 
The histological assessment of these changes will be discussed in the 
following section.
There was no significant difference in the number of 
abnormalities detected in the symptomatic and asymptomatic groups. 
There was also no significant difference in the prevalence of each 
endoscopic abnormality between the two groups.
Histological Assessment of the Gastroduodenal Mucosa
Gastric Mucosa
The gastric mucosa was assessed for the presence of intestinal 
metaplasia, atrophy and gastritis. Each of these was scored from 0- 
5. A score of 0-2 was taken to be within normal limits, and a score 
of 3-5 was viewed as an abnormal result. The findings are shown in 
Table 6. There was no significant difference in the prevalence of 
gastritis, atrophy or metaplasia between the two groups.
Duodenal Mucosa
A similar scoring system was employed for assessment of the 
duodenal mucosa and is shown in Table ! • For the assessment of 
duodenitis a score of 0 or 1 was taken to be normal and a score of 2 
or 3 was regarded as consistent with significant duodenitis. Once 
more there was no significant difference between the two groups.
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Summary
In this study group as a whole 67? of patients had an 
identifiable abnormality on either endoscopic or histological 
assessment of the upper GI tract. There were 15 patients in the 
symptomatic group (75?) with an abnormal examination, compared to 7 
in the asymptomatic group (53?). This difference was not 
significant.
Four patients, all symptomatic, were shown to have a gastric 
ulcer, although there were no duodenal ulcers identified in the study 
group. Histological gastritis was identified in 10 patients and 
histological duodenitis in 16. There was no demonstrable relationship 
between upper GI pathology and renal function or immunosuppression.
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TABLE 5
ENDOSCOPIC ABNORMALITIES IN THE STUDY GROUP
Finding Symptomatic Asymptomatic Total
(N = 20) (N = 13) (N=33)
Oesophagitis 2 1 3
Gastritis 7 2 9
Gastric ulcer 4 0 4
Duodenitis 5 3 8
Duodenal ulcer 0 0 0
Duodenal polyps 5 4 9
Total Number
of patients 14 (10%) 7 (54%) 21 (6335)
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TABLE 6
HISTOLOGICAL ABNORMALITIES IN THE GASTRIC MUCOSA
Symptomatic Asymptomatic Total 
(■ = 20) (H = 13) (H=33)
Intestinal metaplasia 1 0 1
Atrophy 5 3 8
Gastritis 8 2 10
Total Patients 9 (45$) 4 (31$) 13 (39$)
TABLE 7
HISTOLOGICAL ABNORMALITIIES IN THE DUODENAL MUCOSA
Symptomatic Asymptomatic Total
(H = 20) (N = 13) (N=33)
Gastric metaplasia 7 6 ^
Duodenitis 8 8 ^
Total Patients 10(50$) 9(69$) 19(57$)
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Discussion
This is obviously not a comprehensive review of the prevalence 
of upper gastrointestinal disease in renal transplant recipients, a 
subject which has been widely studied in the past* The major 
limitation in achieving this is that when fully informed consent is 
required for this type of invasive procedure there will inevitably be 
a proportion of patients who do not wish to participate. In addition 
it was decided, for practical reasons, to exclude patients who lived 
at a distance from the hospital, and to exclude patients who were 
unwell either due to rejection or to other complications. It was 
also decided that it would not be ethical to stop H2RA therapy prior 
to endoscopy and this may obviously alter the spectrum of disease.
In spite of these limitations, however, those who took part in 
the study and those who declined were comparable for all of the 
parameters studied and particularly were comparable for the 
prevalence of dyspeptic symptoms and H2 receptor antagonist use. It 
therefore seems unlikely that we have preselected a group of patients 
who have an increased prevalence of upper gastrointestinal disease 
when compared to transplant recipients as a whole.
Peptic Dicer
The prevalence of peptic ulcer in the study group was 12^, a 
figure in keeping with many other reports (1,2,12). All of the 
lesions were chronic peptic ulcers and not mucosal erosions. The 
lesions were also pre-pyloric with no duodenal ulcers, a finding 
which is at variance with other reports. It is of course possible 
that H2RA have modified the prevalence of duodenal ulceration.
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All of the patients with peptic ulceration had symptoms of 
dyspepsia, although in two patients the symptoms were mild and these 
two were not on H2RA therapy. During the study period there were no 
complications of peptic ulceration in any of the transplant 
recipients. This observation is in keeping with reports which have 
demonstrated a decreasing incidence of complications, since the very 
high rates reported between 10 and 20 years ago (9,10).
Mucosal Inflammatory Lesions
By far the majority of abnormalities detected at endoscopy were 
mucosal inflammatory lesions without ulceration accounting for 81$ of 
the abnormalities detected and affecting 6656 of the study group.
Duodenitis
Duodenitis was the most common abnormality in the study group, 
occuring in 16 (48$) patients of whom 8 had dyspeptic symptoms. 
These figures relate to histological assessment since endoscopic 
assessment is known to correlate poorly with histological changes 
(203).
The relationship of duodenitis to dyspeptic symptoms remains 
controversial. Cheli et al reported that duodenitis was uncommon in 
asymptomatic patients, being identified in only 6$ of healthy 
individuals (204). These findings, however, were at variance with a 
previous report by Kreuning et al who identified a higher prevalence 
of duodenitis in asymptomatic volunteers (205). One significant 
difference between the two studies was the age of the subjects 
studied. In Cheli*s report the subjects were all under twenty five,
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whereas in the report by Kreuning an older population was studied. 
It may be, therefore, that the distribution of duodenitis in the 
population is age dependent as has been recognised with gastritis.
Once a disease process has been identified in asymptomatic 
individuals its role as a cause of symptoms can be questioned. This 
has certainly been the case with type B gastritis and has also been 
suggested with respect to duodenitis(206). This, however, does not 
seem to be the case and there is strong evidence to dhow symptomatic 
improvement with H2 receptor antagonists (203,207). In addition 
Kreuning et al identified duodenitis in 80# of patients with non 
ulcer dyspepsia (205). Other authors have reported a much lower 
prevalence of duodenitis in symptomatic individuals. Thomson et al 
could identify duodenitis in only 2.8$ of symptomatic patients (208). 
This study, however, relied on endoscopic appearances only and the 
results are therefore not comparable to histological studies of the 
duodenal mucosa.
The relationship of duodenitis to duodenal ulceration has also 
been the subject of some debate. It is certainly true that H2 
receptor antagonists can produce symptomatic and histological 
improvement (207), although histological improvement is disputed by 
some authors (206). There is a strong association between duodenitis 
and type B gastritis (204,206) which would be in keeping with the 
recognised association between type B gastritis and duodenal 
ulceration, and duodenitis has been demonstrated in up to 10035 of 
patients with duodenal ulceration (205). Further evidence to support 
a relationship with duodenal ulceration comes from follow up of 
patients with duodenitis. Thomson et al (208) found that 42# of
91
patients with duodenitis developed duodenal ulceration during a mean 
follow up of 3.5 years, a finding similar to that reported by Jonsson 
(203).
In the study group seven patients with duodenitis were on H2RA 
therapy producing symptomatic improvement in two. It was also 
apparent that duodenitis was as common in the asymptomatic group, 
occuring in 61 ? which is much higher than would be expected from the 
reports discussed above. One possible explanation is that H2 receptor 
antagonists produced symptomatic improvement but did not have an 
effect on the histological abnormality. This, however, does not seem 
to be a likely explanation since only 25? of the asymptomatic 
patients with duodenitis were on H2RA therapy at the time of the 
study.
It is difficult to be sure of the significance of duodenitis in 
the study group. It is certainly a common abnormality but was seen to 
be as common in the asymptomatic group as it was in the symptomatic 
group. Current knowledge of duodenitis in the general population 
would suggest that it is usually associated with symptomatic 
dyspepsia and may therefore be a cause of symptoms in some of the 
study group.
Gastritis
Antral gastritis was the second commonest abnormality, 
occurring in 10 (30?) patients, 8 of whom had symptomatic dyspepsia. 
The role of gastritis in symptomatic dyspepsia has been the centre of 
some debate for many years (57, 206), but studies of Helicobacter 
pylori in the past 8 years have demonstrated resolution of gastritis
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and improvement in symptoms following eradication of the organism 
(73,209).
Five of the patients were on H2RA therapy and had not 
experienced any improvement in their dyspeptic symptoms. This is not 
particularly surprising since it is widely recognised that H2RA have 
no demonstrable effect on the severity of gastritis and are no more 
effective than placebo in relieving the symptoms of dyspepsia 
(57,78).
Oesophagitis
This was the least common endoscopic abnormality being 
identified in only 3 patients, 2 with symptoms. The low prevalence 
of oesophagitis is rather surprising since it has been reported in 
up to 36/6 of transplant recipients (19). Once again however H2RA may 
have modified the clinical picture.
Duodenal Polyps
These were an unexpected and common finding in the study group, 
occurring in 9 (27%) patients, 5 in the symptomatic group and 4 in 
the asymptomatic group. The lesions were broad based and multiple 
usually less than 5mm in diameter, affecting the duodenal cap. In 
all but 2 patients they were associated with duodenitis. The 
inflammatory changes, however, were always mild and the polyps did 
not have the appearance of pseudopolyps which can be seen in 
association with severe duodenitis. Histological examination of 
these polyps revealed duodenal mucosa only and it seems likely that 
these lesions are submucosal.
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There have been no previous descriptions of these lesions in
the literature. While many different polypoidal lesions have been
described in the duodenum, such as adenomas, Brunners gland adenomas 
and hamartomatous polyps, these lesions are uncommon and one would 
not expect a prevalence of 27$ in an unselected group of patients 
(210). One interesting possibility is that these represent areas of 
submucosal lymphoid hyperplasia which has been described producing 
polypoidal lesions associated with cytomegalovirus infections in the 
small bowel of patients with the AIDS (149). The relationship of 
these polyps to cytomegalovirus will be discussed in chapter 6.
Symptomatic Dyspepsia
Endoscopy has revealed that a high proportion of patients (72$) 
had one or more abnormality in the upper GI tract. It seems unlikely 
that the polyps described above could be responsible for symptoms, 
but all of the patients with duodenal polyps had at least one other
endoscopic or histological abnormality and, therefore, if these
polyps are excluded the number of patients with an abnormality of the 
upper GI tract remains unchanged. Of the patients with symptomatic 
dyspepsia 70$ had an abnormality compared with 76$ of the 
asymptomatic group (polyps excluded). This difference is not 
significant. There were, however, more patients in the symptomatic 
group with multiple lesions. The symptomatic group had a mean of one 
lesion per patient compared with 0.46 in the asymptomatic group 
(p<0.05).
An important point to note is that 81$ of patients with an 
abnormality suffered from a mucosal lesion, without ulceration. In
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particular the symptomatic group comprised 14 patients with an 
endoscopic lesion of whom only 4 (29%) had a peptic ulcer.
The importance of non-ulcer dyspepsia has been poorly 
recognised previously in transplant recipients. Chisholm did note a 
high prevalence of dyspepsia in patients with a normal barium meal 
examination, but did not have endoscopic findings to explain this 
(1). It is, of course, possible that the early studies using 
contrast radiology underestimated the prevalence of mucosal 
inflammation in view of the recognised inability of this technique to 
diagnose these lesions. However, even after the introduction of 
endoscopic techniques, mucosal inflammatory lesions were not widely 
reported and the prevalence has varied.
Schiessel et al reported erosions and ulcers together, but did 
not specify the prevalence of each type of lesion (7). Alexander 
identified oesophagitis, gastritis and duodenitis in 36%, 22% and 36% 
respectively in liver transplant recipients (19). Franzin reported a 
similar prevalence of gastritis and duodenitis (8), but neither of 
the studies specified the total number of patients affected by 
mucosal lesions.
The highest prevalence of gastroduodenal lesions is that 
reported by Alijani of 12% (211). In these patients, however, the 
endoscopy was performed within 96 hours of transplantation and within 
48 hours of nasogastric intubation, and the authors do not give 
sufficient details of the lesions to be sure that these were not 
traumatic.
Two further publications report a lower prevalence. Cohen (11) 
found histological gastritis in only 3 of 573 patients (0.005^) and
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Timoney (12) reported duodenitis in 8? of transplant recipients.
The reasons for the wide discrepancy in the studies reported 
above may be related to the diagnostic methods used and to the timing 
of endoscopy. As discussed previously the correlation of endoscopic 
and histological abnormalities is poor, and it may not be valid to 
assume that the prevalence of upper GI lesions is independent of time 
elapsed since transplantation. Indeed available evidence would 
suggest that the factors which may contribute to upper GI tract 
disease will improve with time. Steroid administration and 
immunosuppressive therapy will be reduced, gastric acid secretion 
will return towards normal levels (17) and peak incidence of viral 
infection will occur within the first 2 months following 
transplantation (122).
If the studies reporting extremes of prevalence are examined in 
detail we find that histological evidence was not used (12,211), 
whereas in the studies reporting a prevalence of 35-55? histological 
assessment of the upper GI tract was also available (8,19),and are in 
keeping with the data from the study group.
Relationship to Renal Function and Immunosuppression
There was no significant association between any of the 
indentified pathologies and serum urea, creatinine, cyclosporine or 
prednisolone dose. The mean urea and creatinine in the study group 
were 10.7mmol/l and l66umol/l respectively and, although outside of 
the normal reference range, they are not markedly abnormal. Previous 
work would not lead one to expect a profound influence on the upper 
GI tract since none of the reported studies have demonstrated any
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convincing association between upper GI tract disease and renal 
function (7,12,24). The mean prednisolone dose was I8.4mg and would 
not necessarily be associated with a high risk of upper GI tract 
disease(37,39). The influence of cyclosporine on the upper GI tract 
is more difficult to assess. Many of the early studies into peptic 
ulceration in transplant recipients were performed prior to the 
introduction of cyclosporine. Knechtle (9,10) demonstrated a 
reduction in the complications of peptic ulceration following the 
introduction of cyclosporine but the other variables discussed in 
chapter 1 also changed over the same period of time.
Conclusions
The results of the endoscopic and histological examination of 
the gastroduodenal mucosa has highlighted a high prevalence of 
mucosal inflammatory lesions without ulceration. None of these 
lesions however were significantly associated with symptomatic 
dyspepsia. There was a strong tendency for gastritis to be commoner 
in symptomatic patients and it may be that a significant difference 
would have been observed if larger patient numbers could have been 
recruited. Duodenitis, however, was commoner in the asymptomatic 
group which is surprising in view of the association with symptomatic 
dyspepsia in the general population (204,205). The prevalence of 
ulceration in the study group was 12$ which is in keeping with 
published reports although the preponderance of gastric ulcers is 
slightly unusual. It is possible, however, that H2RA therapy may 
have influenced this. There was no association between GI pathology 
and renal function or immunosuppression and the aetiology of these
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lesions has not been explained. This w i n  be discussed in more 
detail in the following two chapters with respect to Helicobacter, 
Cytomegalovirus and Herpes simplex.
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CHAPTER 5
HELICOBACTER PILORI
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Prevalence of Helicobacter Pylori
Helicobacter pylori was detected by either urease slide test or 
by histology in 16 patients. The sites of colonisation and the 
distribution in the two subgroups is shown below in Table 8.
All of the patients colonised by H pylori had involvement of 
the gastric antrum. In two patients the organism was also identified 
histologically in the duodenal biopsy specimens. The prevalence of 
H pylori was significantly higher in the symptomatic group (p=0.02), 
although there was no association with any particular symptom 
(Table 9).
Comparison of Detection Methods
Of the 16 patients identified as H pylori positive this was 
identified histologically in 15* and by the urease slide test in 
eleven. In one patient the slide test alone was positive, leaving 5 
patients diagnosed solely by histology (Table 8).
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Method
Urease slide 
(Gastric only)
Histology
(Gastric)
Histology 
(Duodenal)
Total patients 
colonised
TABLE 8
PREVALENCE AND DISTRIBUTION OF H PYLORI 
Number Positive
Symptomatic Asymptomatic By Each Method
(N=20) (N=13) (N=33)
10 1 11
12 3 15
2 0 2
13 (6535) 3 (2335)* 16 (48J5)
*p=0.02 (Fishers exact test)
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TABLE 9
ASSOCIATION OF H PYLORI WITH UPPER GI SYMPTOMS
Symptom H pylori + H pylori - Total
(N = 13) (N = 7) (N=20)
Pain 8 (61*) 5 (71*) 13
Heartburn 0 1 (14*) 1
Anorexia 0 1 (14*) 1
Nausea 9 (69*) 5 (71?) 14
102
Relationship of H Pylori to Endoscopic and Histological Abnormalities
The association of H pylori with endoscopic abnormalities and 
with histological gastritis and duodenitis was assessed. These 
results are summarised in Table 10.
The results demonstrate a significant association between H 
pylori colonisation gastritis, and gastric ulceration, although 
there was no significant association with oesophagitis, duodenitis, 
or duodenal polyps.
Relationship of H Pylori to Atrophy and Metaplasia
Table 11 illustrates the relationship of H pylori to metaplasia 
and atrophy in gastric and duodenal specimens.
There was no significant difference in the distribution of 
gastric H pylori in patients with intestinal metaplasia and gastric 
atrophy of the antral mucosa or gastric metaplasia of the duodenal 
mucosa. The effects of duodenal colonisation could not be assessed 
since only 2 patients were affected, one with gastric metaplasia and 
one without.
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TABLE 10
RELATIONSHIP OF H PYLORI TO ENDOSCOPIC AND HISTOLOGICAL 
ABNORMALITIES IN THE UPPER GI TRACT
Abnormalities H pylori 
(N=16)
Oesophagitis 1
Gastritis 10
Gastric ulcer 4
Duodenitis 7
Duodenal polyps 4
* P=0.0001 
«« P=0.04
+ H pylori - Total
(N=17) (N=33)
2 3
0 10 *
0 4 «*
9 16
5 9
exact test) 
exact test)
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TABLE 11
RELATIONSHIP OF H PYLORI TO ATROPHY AND METAPLASIA
H pylori + H pylori - Total
(N=16) (N=17) (N=33)
Gastric Mucosa
Gastric atrophy 5 3 8
Metaplasia 5 1 6
Duodenal Mucosa
Metaplasia 5 6 11
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Relationship to Renal Function, Immunosuppression and Age
The prevalence of H pylori colonisation was also assessed with 
respect to renal function, immunosuppression and age. These results 
are summarised in Table 12.
There was no significant difference in mean age or mean 
Cyclosporine levels between the 2 groups. There was a tendency 
towards higher serum urea and creatinine and a higher Prednisolone 
dose in those who were H pylori positive, but this was not 
significant. There was no significant difference in the mean age of 
the two groups. In addition there was no significant difference in 
the prevalence of H pylori in different age groups (44? in those 
greater than 40 and 53? of those 40 and under).
Time Elapsed Since Transplantation
The mean time between transplantation and endoscopy was 13.5 
weeks (range 8-19). For H pylori positive patients this was 13.4 
weeks (range 10-18) and for H pylori negative it was 13.6 weeks 
(range 8-19): a non-significant difference.
Summary
Sixteen of the patients in the study group (48?) had 
Helicobacter pylori in the gastric antrum. In addition 2 of these 
patients had colonisation of the duodenum. Helicobacter pylori was 
significantly more common in patients with symptomatic dyspepsia and 
all of the patients in the study group with gastritis or gastric
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ulcer were H pylori positive (p=0.0001, p=0 04)
» v w.uh;. There was
significant association between H nvloni =
pylon and other endoscopic
histological abnormalities, with serum urea, creatinine, prednisolone 
dose, Cyclosporine levels, age or time elapsed since transplantation.
no
or
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TABLE 12
RELATIONSHIP OF H PILORI TO RENAL FUNCTION, 
IMMUNOSUPPRESSION AND AGE
H pylori + H pylori -
(N=16) (N=17)
Mean urea (mmol/1) 11.9 9.6
Mean creatinine (umol/1) 182 152
Mean serum Cyclosporine 126 133
(nmol/I)
Mean Predinoslone dose 20.4 16.4
(mg/day)
Mean Age (years) 42.5 38.8
108
Discussion
Prevalence.
The prevalence of H pylori in the study group was 48$. The 
difficulty in interpreting this lies in the recognised high 
prevalence of the organism in the general population. Ideally a 
control group should have been used, but obviously patients attending 
for upper GI endoscopy are a pre-selected population who are likely 
to have a high prevalence of H pylori. To obtain a truly 
representative group therefore, healthy volunteers would have to have 
been employed, age and sex matched for the study group. There are, 
however, many difficulties in conducting invasive investigations in 
healthy individuals.
For this reason the precise prevalence of H pylori is difficult 
to determine. Most studies have relied on indirect methods such as 
urea breath testing or serology. Studies using these methods have 
demonstrated a prevalence of 20-30$, but have also demonstrated 
striking variations with age, socioeconomic status and ethnic origins 
(111,212).
Serological studies have demonstrated a high prevalence of H 
pylori antibodies in up to 32$ of asymptomatic individuals and have 
confirmed an increasing prevalence with age, rising from 10$ in those 
under 25 to 60$ in those over 55 (104,112).
It is likely however, that serological studies will 
overestimate the prevalence of infection. Rathbone et al 
demonstrated detectable H pylori antibodies in all patients with non
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ulcer dyspepsia, and although the mean IgG and IgA titres were higher 
in patients who were H pylori positive, there was considerable 
overlap with those who were H pylori negative (106). Von Wulfen et 
al found positive antibody titres in 41$ of H pylori negative 
patients and in 46$ of H pylori positive patients (104), and Vaira 
demonstrated a fall in antibody titres following eradication of the 
organism, but the titres did not return to normal levels (105). It 
seems, therefore, that positive titres, while indicative of previous 
exposure to the organism, correlate poorly with active infection.
Urea breath testing on the other hand has been demonstrated to 
have a high specificity for H pylori and this technique is likely to 
give a more accurate estimate of the prevalence in the general 
population (213). Graham et al studied asymptomatic individuals by 
urea breath testing and found an increase in prevalence from 5$ in 
patients under 45 to 75$ in those over 65 (212). The same authors 
also demonstrated a 20$ prevalence in US citizens compared to 46$ in 
Indians and 60$ in Chinese (111).
In the study group the mean age of H pylori positive patients 
was 42.5 compared to 38.8 in those who were H pylori negative. This 
difference was not significant and, in addition, there was no 
significant difference in the prevalence of the organism in patients 
under 40 when compared to those 40 and over.
When these factors are taken into account therefore, there 
appears to be a higher prevalence of H pylori in the study group than 
would be expected in an unselected group of normal individuals.
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ttofcantion of H Pvlori.
In all but one patient who was found to be H pylori positive 
this was detected on histological examination, leaving only one 
patient diagnosed by urease slide test alone. in the 15 patients 
with histological evidence of H pylori CLO test was positive in 11 
(73J) which is consistent with previous reports for single biopsy CLO 
test (60,189).
Distribution and Relationship to GI Pathology
All 16 patients positive for H pylori had evidence of gastric 
colonisation and 2 of them (12.5$) had H pylori identified in the 
duodenum. This distribution is in keeping with previous reports in 
the general population which have demonstrated a much higher 
prevalence of H pylori in the antrum, with duodenal involvement in 
between 2$ and 18$ of cases (214,215). In addition duodenal 
involvement is almost invariably associated with antral colonisation 
(62,215).
In our study group there was a strong association between 
H pylori and gastritis. All ten patients with histological gastritis 
had evidence of H pylori in the gastric antrum. Unusually perhaps, 
six patients with H pylori did not have gastritis using our scoring 
system. Part of the explanation for this is the arbitrary cut off 
which was chosen and all H pylori patients with one exception, did 
have gastritis graded at one or above. Interestingly the H pylori 
Positive patient who did not have histological evidence of gastritis
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was the patient identified by urease slide test alone. It may be, 
therefore, that this represents a false positive CLO test, which 
would be unusual (60), or it reflects the patchy nature of H pylori 
and gastritis which is perhaps the more likely explanation (189).
There was also a positive correlation with gastric ulceration, 
all 4 of our patients being H pylori positive. This is a slightly 
higher percentage of patients than might be expected (94,95) but 
probably reflects the small number identified in the study group.
In the study group there was no demonstrable association 
between H pylori and oesophagitis, duodenitis or duodenal polyps.
The relationship of H pylori to oesophagitis seems likely to be 
a casual association. Walker et al identified H pylori in only 25$ 
of patients with oesophagitis, but this was invariably associated 
with gastric Helicobacter (215). In addition they identified 
oesophageal H pylori in only 29$ of patients with Barrats oesophagus 
where a high prevalence of H pylori would perhaps be expected.
The importance of Helicobacter as a cause of duodenitis is 
difficult to ascertain. As discussed above H pylori is found in up 
to 18$ of duodenal biopsies but is almost always accompanied by 
antral involvement, leading some authors to suggest that it is merely 
a commensal (215). Other authors, however, have reported a much 
stronger association between H pylori and duodenitis. Johnstone et 
al reported duodenal H pylori in 100$ of patients with active 
duodenitis and no H pylori identified in patients without duodenitis 
(62). Wyatt et al identified gastric Helicobacter in 88$ of patients
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with duodenitis and duodenal H pylori in 5335 (91). In an earlier 
study Steer identified H pylori adjacent to duodenal ulcers in 73$ 
of patients (216).
In our group 43$ of patients with duodenitis had H pylori in 
the gastric antrum but in the duodenum in only 12$. In addition 56$ 
of patients with gastric Helicobacter had no evidence of duodenitis. 
If we relax our diagnostic criteria and include a score of one or 
above we can show duodenitis in 87$ of H pylori positive individuals, 
but also duodenitis in 94$ of H pylori negative individuals.
Although our results are at variance with those of Wyatt, 
Johnstone and Steer they are compatible with those reported by Walker 
(215). They are also in keeping with a recent report by Shousha et 
al who found H pylori in the duodenum of 9$ of patients, despite 
identifying gastric metaplasia of the duodenal mucosa in 62$ (90). 
Interestingly this occurred in a group of patients with renal failure 
on dialysis. The authors concluded that the duodenal environment in 
haemodialysis patients is hostile to H pylori, although the reasons 
why this should be are unclear.
■Relationship to Symptomatic Dyspepsia
There was a significantly higher prevalence of H pylori in 
patients with symptomatic dyspepsia compared to those who were 
asymptomatic; thirteen out of twenty in the symptomatic group, 
compared with three out of thirteen asymptomatic patients. If the 
symptomatic group are subdivided, however, there is no significant
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association with any particular upper GI symptom.
The relationship of H pylori and gastritis to symptomatic 
dyspepsia has already been discussed in Chapters 2 and 4 and the 
results are consistent with previous reports.
Relationship to Renal Function and immunosuppression
The relationship of H pylori to renal function is difficult to 
ascertain. In the study group the mean serum urea and creatinine 
were no higher in H pylori positive patients. Only one previous 
study has reported H pylori in renal failure patients on 
haemodialysis (90). This revealed a very low prevalence of H pylori 
(2.556), although the report dealt with duodenal involvement only and 
did not comment on gastric colonisation. There are theoretical 
reasons why an elevated blood urea may encourage H pylori by 
increasing the substrate available for urease, thereby creating a 
favourable environment for growth of the organism. In transplant 
recipients and haemodialysis patients, however, it seems unlikely 
that blood urea will be sufficiently elevated for this to be an 
important factor and there are no reports of H pylori in untreated 
renal failure.
A complicating factor in the study group is that renal function 
may not be independent of immunosuppression. Compromised renal 
function is often a manifestation of rejection and will be 
accompanied by an increased dose of immunosuppressive drugs. In the 
study group the mean prednisolone dose was not significantly higher
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in H pylori positive patients, and there was no difference in serum 
cyclosporine levels.
The precise role of immunosuppression in helicobacter 
infection is unclear. There are no reports in the literature of H 
pylori in transplant recipients. One recent publication by Francis 
et al has reported the prevalence of H pylori in patients who are HIV 
positive (217). The authors demonstrated that 14% of HIV positive 
patients were H pylori positive compared with 4856 of control 
subjects, and the authors concluded that the immunosuppression 
associated with AIDS was not of importance in the normal immune 
response to H pylori. There are, however, several problems with this 
interpretation. Firstly the control group were drawn from a 
population of dyspeptic patients who are likely to have a high 
prevalence of H pylori and, secondly, the study group comprised 51 
patients who were HIV positive only 16 of whom had AIDS. The immune 
status of these patients, therefore, was unknown and it is difficult 
to be certain that T cell suppression is not a factor in H pylori 
infection. The role of the immune response to H pylori and the 
effects of immunosuppression will be discussedin Chapter 8.
Conclusions
The study group has been demonstrated to have a high prevalence 
of H pylori (4856). It is difficult to be certain that this is higher 
than in the general population, primarily because of the difficulty 
in establishing the precise prevalence in a healthy population. The
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available evidence would suggest, however, that the prevalence in an 
age matched group of healthy individuals is likely to be less than 
20?. One important factor which supports a pathogenic role is the 
significantly higher prevalence of H pylori in the symptomatic group. 
It is unfortunate that a larger patient group was not available to 
allow a definite answer to be obtained. There are inevitable 
difficulties in performing large endoscopic population studies and 
perhaps it would now be appropriate to study transplant recipients by 
non invasive methods such as urea breath testing.
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CHAPTER 6
CYTOMEGALOVIRUS AND HERPES SIMPLEX
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CYTOMEGALOVIRUS
Prevalence of Cytomegalovirus in the Study Group and Control Tissue
The prevalence of cytomegalovirus was determined in biopsy 
material from the gastroduodenal mucosa of the study group and in 
normal gastric and duodenal biopsies obtained from fixed tissue 
stored in the Department of Pathology. In the study group there were 
33 biopsy specimens from each site and in the control group there 
were 36 gastric and 25 duodenal biopsies. All of the specimens were 
examined by immunohistochemistry.
The number of positive results detected by immunohistochemistry 
is summarised in Table 13. In the control group the gastric and 
duodenal biopsies were obtained from different subjects and the data, 
therefore, is expressed as the number of positive biopsies. There 
was a significantly higher prevalence of cytomegalovirus in the study 
group as a whole and a significantly higher prevalence in the 
duodenal mucosa. There was, however, no difference in the prevalence 
of cytomegalovirus in the gastric mucosa of the study group when 
compared to the control subjects.
In the study group 19 biopsy specimens were positive. In three 
patients both sites were involved and in the remainder only one site 
was found to contain virus. Sixteen patients (48£), therefore, had 
evidence of cytomegalovirus in the gastroduodenal mucosa (Figs 15- 
17).
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Figure 15: H & E section of duodenal mucosa showing cytomegalic
cells the glandular epithelium.(x40)
Figure 16: Immunohistochemical section of duodenal mucosa stained 
with anti CMV. The cytomegalic cells in the epithelium 
stain brown with peroxidase.(x25)
Figure 17: Higher magnification of Figure 16 illustrating
the striking nuclear enlargement when compared 
to the normal epithelial nuclei.(x40)
TABLE 13
PREVALENCE OF CYTOMEGALOVIRUS IN THE GASTRODUODENAL 
MUCOSA OF TRANSPLANT RECIPIENTS AND CONTROL SUBJECTS
Control Group 
N = 61
Study Group 
N = 66
Gastric
Duodenal
Total
5/36
2/25
7
* p = 0.006 (Fishers exact test) 
** p = 0.027 (Chi squared test)
6/33
13/33*
19**
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Distribution within the Gastroduodenal Mucosa
Cytomegalovirus was identified in the gastric mucosa of six 
patients and in the duodenal mucosa of thirteen patients. In the 
gastric mucosa all positive staining was in the lamina propria and 
there was no evidence of epithelial involvement. In the duodenal 
biopsies positive staining was seen in the lamina propria in nine and 
in the epithelium in seven. In three patients, therefore, both sites 
were involved (Table 14)
Relationship of Cytomegalovirus to Pathology and Dyspepsia
The prevalence of cytomegalovirus in each pathological 
abnormality is shown in Table 15. Oesophageal biopsy material was 
not available and therefore oesophagitis has been omitted. The data 
for gastric and duodenal pathologies relate to cytomegalovirus in the 
gastric and duodenal mucosa respectively. Cytomegalovirus was 
significantly associated with duodenitis, but not with gastritis, 
gastric ulceration or duodenal polyps.
In the control group the gastric and duodenal mucosa was normal 
and therefore a further control group was employed matched to the 
study group for gastritis and duodenitis, consisting of ten and 
sixteen patients respectively. No CMV was identified in any of the 
biopsy material from this second control group (p<0.001, Fisher’s 
exact test).
There was no association between cytomegalovirus and 
symptomatic dyspepsia, virus being identified in 45^ of symptomatic 
patients and in 5356 of asymptomatic patients (Table 16).
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TABLE 14
DISTRIBUTION OF CYTOMEGALOVIRUS WITHIN 
THE GASTRODUODENAL MUCOSA
Lamina Propria Epithelium Total Patients
Duodenal 9 7 13
Gastric 6 0 6
Total 13 7
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TABLE 15
RELATIONSHIP OF CYTOMEGALOVIRUS TO GASTRODUODENAL PATHOLOGY
CMV+ CMV-
N = 16 N = 17 Total
(6 gastric, 13 duodenal)
Gastritis 2 8 10
Gastric ulcer 0 4 4
Duodenitis 11 5 16*
Duodenal polyps 2 7 9
*p = 0.001 (Fishers exact test)
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Relationship of Gastroduodenal Cytomegalovirus to Systemic 
Cytomegalovirus Infection
Data on pre and post transplant CMV serology and donor serology 
was available for twenty five patients and is summarised in table 17. 
Primary infection was defined as infection ocurring in a seronegative 
recipient and reccurrent when in a seropositive recipient. Infection 
was detected by complement fixation test and by IgM titres. No 
significant association could be demonstrated between CMV serology 
and identification of the virus in the gastrointestinal tract.
Relationship of Cytomegalovirus to Renal Function and 
Immunosuppression
The mean serum urea, creatinine and cyclosporine,and the mean 
prednisolone dose are shown in table 18 for CMV positive and for CMV 
negative patients. There was no relationship between urea or 
cyclosporine and gastroduodenal cytomegalovirus. There was a 
tendency for the CMV positive patients to have a higher mean 
prednisolone dose, but this did not reach statistical significance 
(p=0.3). There was also a tendency towards a higher mean creatinine 
in the CMV negative patients but once more this did not achieve 
statistical significance(p=0.2).
Relationship of Cytomegalovirus to Age and Time Elapsed
Since Transplantation
The mean age and the time elapsed since transplantation for 
both the positive and negative groups are summarised in Table 17. 
There was no statistical association between either of these
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parameters and CMV infection.
Herpes Simplex Virus in the Upper Gastrointestinal Tract
Herpes simplex virus was looked for in the gastric and duodenal 
mucosa by immunohistochemistry in the study group and in control 
tissue. This comprised thirty three biopsies from the stomach and 
from the duodenum in the study group and thirty six gastric and 
twenty five duodenal biopsies in the control group; one hundred and 
twenty seven seperate specimens. No positive staining could be 
identified in any of the biopsy specimens
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TABLE 16
RELATIONSHIP OF CYTOMEGALOVIRUS TO SYMPTOMATIC DYSPEPSIA
Symptomatic Asymptomatic
N = 20 N = 13
Gastric CMV 4 2
Duodenal CMV 7 6
Total patients positive 9 7
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TABLE 17
RELATIONSHIP OF GASTRODUODENAL CYTOMEGALOVIRUS 
TO SYSTEMIC CMV INFECTION
Gastroduodenal CMV 
CM? + CMV -
(N=10) (N=15)
Seronegative
Seropositive 
no Recurrence
Primary Infection
Secondary Infection
Total
3
6
7
9
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TABLE 18
THE RELATIONSHIP OF CYTOMEGALOVIRUS TO 
RENAL FUNCTION AND IMMUNOSUPPRESSION
CMV+ CMV - “
H=16 N=17
Mean urea (mmol/1) 10.1 11.3
Mean creatinine (umol/1) 145 187
Mean cyclosporine (nmol/1) 131 128
Mean prednisolone dose (mg) 20.8 16.2
Mean age (years) 39.7 42.5
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Discussion
prevalence
The prevalence of cytomegalovirus in the study group was 4856 
and was significantly higher than in the control group. This 
prevalence is comparable to 45% reported by Franzin (8) and 3356 
reported by Alexander (19). Neither of these studies, however, had a 
normal control group and it was impossible to be certain that this 
apparent high prevalence was not seen in the general population. The 
results of this study have shown that the virus can be identified in 
the gastroduodenal mucosa of normal individuals but at a lower 
prevalence than is seen in transplant recipients.
One potential criticism could be that the control biopsy 
specimens were of normal gastroduodenal mucosa, and it may be argued 
that if specimens with gastritis and duodenitis had been used as 
controls the prevalence may have been higher. For this reason a 
second control group was used, matched to the study group for changes 
of gastritis and duodenitis. In the second control group no CMV was 
identified in ten biopsies with gastritis or in sixteen biopsies with 
duodenitis (p<0.001).
Association with Pathology and Dyspepsia
Duodenitis was the only pathological abnormality associated 
with cytomegalovirus. Eleven of 16 patients with histological 
duodenitis had CMV in the duodenal mucosa and only two patients with 
duodenal CMV had a histologically normal mucosa. This is in keeping 
with the report by Alexander et al (19) who found a significant 
association with duodenitis but not with gastritis or oesophagitis.
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Franzin, however, could demonstrate no significant association 
between CMV and inflammatory lesions of the gastric or duodenal 
mucosa (8). The other reports which had studied CMV in the 
gastroduodenal mucosa did not include any transplant recipients with 
a normal mucosa and could not comment on the association of CMV with 
particular pathological lesions (11,15,142).
In spite of a significantly increased prevalence of CMV in the 
study group and a significant association with duodenitis there was 
no demonstrable association between CMV infection and symptomatic 
dyspepsia. Once more this finding is entirely in keeping with 
Alexanders report and also with Franzin's findings relating to 
symptomatology.
In contrast to the anecdotal and uncontrolled reports these 
results do not support the veiw that CMV is a cause of peptic 
ulceration or gastritis. In our study group there was no association 
with peptic ulcer as suggested by Franzin and Cohen (8,11). These 
papers, however, were retrospective and did not have control 
specimens from non-transplant patients and the association may have 
been coincidental. Cohen reported cytomegalovirus in 62$ of peptic 
ulcers or erosions in renal transplant recipients and concluded that 
CMV played an important role in the pathogenesis of these lesions 
(11). The prevalence of 62$ and small numbers involved could well 
have given rise to a casual association with peptic ulceration and is 
not widely at variance with the prevalence in our study group as a 
whole. Similarly the prevalence reported by Millard at post-mortem 
of 12$ (142) is much lower than ours and does not support a 
pathogenic role. Diethelm et al reported CMV as a cause of
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haemorrhagic gastritis, (15) and while this may occur it would not 
appear to be a common complication in the upper GI tract.
A further factor which may have a bearing on this is the small 
number of peptic ulcers in our study group. As discuused previously 
the use of H2 receptor antagonists may have modified the spectrum of 
disease. Most reports would suggest a peptic ulcer prevalence of 
around 10$ in transplant recipients and therefore a large study 
population would be required to highlight any significant 
relationship with CMV infection.
There was also no relationship between CMV and duodenal polyps. 
As discussed in Chapter 4 the mucosa of these polyps was either 
normal or showed changes of duodenitis. This therefore suggested 
that the lesions were submucosal and gave rise to the interesting 
possibility that these were cases of submucosal lymphoid hyperplasia 
which has been reported to occur in association with CMV (149). From 
our results this does not apear to be the case and the aetiology of 
these polypoidal lesions remains unclear.
Distribution within the Gastroduodenal Mucosa
Previous reports of cytomegalovirus in the upper and lower GI 
tract have tended to show contradictory results with respect to the 
distribution of virus within the epithelium and lamina propria.
In our study group all gastric lesions were in the lamina 
propria with no epithelial involvement. In contrast the duodenal 
epithelium was seen to be involved in seven out of 13 patients, 
although in 9 of the 13 the lamina propria was involved leaving only 
four patients with purely epithelial involvement.
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These results are consistent with Cohen who reported 
involvement of the lamina propria in all of eight patients and 
concurrent epithelial involvement in seven (11), Included in this 
group were four gastric specimens three of which showed evidence of 
virus within the epithelial cells: a feature which we did not see. 
Hinnant also reported a preponderance of virus within the lamina 
propria in the lower GI tract, finding that only 10$ of the involved 
cells were epithelial (147).
Conversely Franzin et al identified a preponderance of 
epithelial cells affecting the surface and glandular cells of both 
gastric and duodenal specimens, with relative sparing of the lamina 
propria (8).
A possible explanation for these discrepancies is that Franzin 
identified viral infection by cytomegalia alone, and in our series 
the only cytomegalic cells identified were epithelial, all cells in 
the lamina propria being identified by immunohistochemistry. If our 
study had, therefore, been performed without special histological 
techniques we too would have identified only epithelial involvement 
and only duodenal involvement along with a much lower prevalence of 
viral infection.
Comparison of Detection Methods,
CMV was identified by immunohistochemistry in sixteen patients. 
An important feature was the demonstration of CMV in 10 of the 16 who 
did not show evidence of CMV on routine histological examination. 
This difference was particularly marked in the lamina propria. This 
is in keeping with reports by Jiwa and Niedobatek (196,195) who
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identified histological changes in only 43* and 60* respectively of 
patients who were positive by immunohistochemistry. Both of these 
publications reported on a wide variety of tissues although neither 
reported on the gastrointestinal tract and CMV has not been studied 
previously in the GI tract by immunohistochemistry.
The increased detection rate of CMV by the use of these methods 
would suggest that previous reports, relying on histology alone, have 
underestimated the prevalence of infection in the upper GI tract 
(8,11). One report on the results of culture of endoscopic biopsies 
would suggest that this too is a sensitive method although is perhaps 
technically more difficult, requiring rapid transport of specimens 
and access to virology facilities (19). The advantage of the method 
used in this study is the ability to perform the techniques on 
endoscopic biopsy material processed for standard histological 
examination.
Gastroduodenal Cytomegalovirus and Systemic Infection
There was no demonstrable relationship between CMV serology and 
identification of the virus in the GI tract. The most difficult 
aspect of this to explain is the presence of virus in two 
seronegative patients. Seronegativity wold imply that the patient 
has never been exposed to the virus and therefore the 
immunohistochemistry gave rise to spurious results. With this in 
mind the sections relating to these two patients were reviewed and 
cytomegalic cells were identified staining positively for CMV.
Another possible explanation is that the patients had not 
seroconverted at the time of endoscopy and that follow up with
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further blood sampling for antibody titres would have revealed 
increasing antibody titres over a period of time. It is also possible 
that the patients had been exposed to the virus but that their 
antibody levels had fallen to undetectable levels. This last option 
is likely to be a rare occurrence although it has been reported 
(218).
Only one of the previous reports on gastrointestinal CMV 
studied patient serology and all of the patients were seropositive. 
No conclusions could be drawn, therefore, from this study regarding 
the influence of the patients* serological status (19).
Relationship to Immunosuppression and Renal Function
There was no significant relationship between gastrointestinal 
CMV and the immunosuppressive regime or renal function. While there 
is a well recognised relationship between CMV, the increased 
immunosuppression and deteriorating renal function associated with 
graft rejection (161) none of the patients in the study group 
suffered from acute rejection episodes at the time of endoscopy and 
consequently any differences in immunosuppression and renal function 
were modest and would be unlikely to show any significant difference.
Conclusions
This study has shown a high prevalence of CMV in the 
gastroduodenal mucosa of renal transplant recipients as suggested by 
previous reports (8,19)* In addition it has demonstrated that the 
prevalence of CMV is higher than in the normal population and has 
defined the prevalence in the general population to be around 11$.
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It has confirmed the poor specificity of routine histology in 
detecting cytomegalovirus, which was recognised in some organ 
systems, but was not previously recognised in the gastrointestinal 
tract (195, 196).
The presence of CMV was associated with duodenitis but no other 
pathological abnormality, and although CMV is present in a high 
proportion of transplant recipients it is not a major cause of upper 
GI pathology as suggested by some authors (8,11,15,142), and the 
presence of CMV inclusions in peptic ulcers may merely be a casual 
association. CMV was not, however, associated with symptomatic 
dyspepsia and its importance in dyspepsia is more difficult to 
evaluate. The presence of CMV in asymptomatic individuals does not, 
however, necessarily rule out cytomegalovirus as a cause of dyspepsia 
in some individuals.
Herpes Simplex Virus
One hundred and twenty seven gastric and duodenal biopsies were 
examined by immunohistochemistry for Herpes simplex virus with no 
positive staining. This is perhaps a slightly surprising result in 
view of the prevalence of HSV infection in renal transplant 
recipients and previous reports of HSV infection in the
gastrointestinal tract.
The prevalence of Herpes simplex infection in transplant 
recipients has been reported to be between 14 and 70%, usually 
occurring within the first six months following transplantation, 
(165,219), and although gastrointestinal HSV is an uncommon event 
(178,182) some series have reported a high prevalence m
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immunosuppresed patients (176).
There are several possible explanations why our results are 
different from those which might have been expected. These include 
the site of involvement, the population under study and the detection 
methods used.
The largest study of gastrointestinal Herpes simplex was that 
reported by Buss and Scharyj in 1979 (176). This was a post mortem 
study of patients who had died of disseminated HSV infection. Fifty 
six patients were studied, fifty of whom were found to have herpetic 
oesophagitis. An important factor in this report which is of 
relevance to the work contained in this thesis is that only one of 
the fifty patients had evidence of herpetic infection in the gastric 
mucosa. In our study biopsy material was not taken from the 
oesophagus.
The report by Buss and Scharyj also differs from ours in the 
patient population studied. Firstly the patients had died of 
disseminated Herpes simplex infection, although only seven of the 
patients were recognised as having clinical HSV ante mortem. The 
second difference is that the study population consisted of patients 
undergoing chemotherapy for malignant disease and were more 
profoundly immunosuppressed than would be normal in renal transplant 
recipients.
The third factor to be taken into account are the methods 
employed to detect Herpes simplex. The majority of reports, 
including that by Buss and Scharyj, relied on histopathological 
detection of the viral cytopathic effect (176,182,220,221). The 
typical histological features consist of intranuclear inclusions and
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multinucleate giant cells, usually found in the epithelium adjacent 
to ulcer margins (220). These feature, however, are not specific and 
can be produced by Varicella zoster and Cytomegalovirus and apparent 
nuclear inclusions have also been demonstrated in the absence of 
viral disease (222). None of these histological features were 
identified in our biopsy material.
It is possible that immunohistochemistry failed to identify 
virus present in the biopsy material. This, however, is an unlikely 
possibility. Immunohistochemistry obviously relies on the presence of 
viral protein as the antigen and it could be argued that viral DNA 
may be present and could be detected by in situ hybridisation. This 
is unlikely, however, since viral DNA in the absence of viral protein 
would imply that the gastroduodenal mucosa is a site of viral latency 
and this has certainly not been recognised to date. Further study of 
the biopsy material, however, will be performed using viral DNA 
probes to ensure that this is not the case.
Since one would expect immunohistochemistry to be a more 
sensitive detection method than histology alone, and should be as 
sensitive as insitu hybridisation, the conclusion must be that Herpes 
simplex is not present in the gastric or duodenal mucosa of renal 
transplant recipients.
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CHAPTER 7
MUCOSAL T LYMPHOCYTE SUBSETS
137
INTRODUCTION
Mucosal T lymphocytes were studied in gastric and duodenal 
biopsies which were frozen in liquid nitrogen and subsequently 
stored. Tissue was available from the stomach and duodenum of 
fifteen transplant recipients. In addition a prospective group of 
normal control tissue was obtained and frozen. In this control group 
tissue was obtained for urease slide test analysis and the patients 
were matched to the transplant recipients for age and Helicobacter 
status.
The antibodies used were for Leu 2 (Suppressor/cytotoxic) and 
Leu 3 (Helper/inducer) and the results are expressed as the mean T
p
lymphocyte count per mm . The ratio of Leu3 to Leu 2 was also 
calculated and is expressed as the mean of the ratios.
Transplant Recipients and Controls
The data for T lymphocyte subsets in the gastroduodenal mucosa 
of both the 3tudy group and the control group are summarised in table 
19. There was no significant difference between either subset or the 
Leu3:Leu2 ratio in the two groups.
Relationship to Immunosuppression and Renal Function
Each of the T cell markers and the Leu3:Leu2 ratio was assessed 
with respect to serum urea, cyclosporine, creatinine and prednisolone 
dose for both the gastric and duodenal mucosa in the transplant 
recipients.
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TABLE 19
T LYMPHOCYTE SUBSETS IN TRANSPLANT 
RECIPIENTS AND CONTROLS
TRANSPLANT CONTROLS
(N=15) (N=15)
Leu2 (gastric) 133 154
Leu2 (duodenal) 88 94
Leu3 (gastric) 189 243
Leu3 (duodenal) 194 223
L3:L2 ratio (gastric) 1.71 2.08
L3:L2 ratio (Duodenal) 2.58 2.69
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There was a positive correlation between Leu3 and serum 
creatinine in the duodenal mucosa (r=0.52,p=0.04) and a positive 
correlation between the Leu3iLeu2 ratio and both urea and creatinine 
in the duodenum (r=0.54, p=0.03 for both). These relationships are 
summarised in figures 18,19 and 20. There was no significant 
relationship between T lymphocyte subsets and the other parameters. 
The correlation coefficients and significance levels are illustrated 
in table 20.
Relationship to Gastritis and Duodenitis
The influence of gatritis and duodenitis on T cell subsets is 
summarised in table 21. There was a tendency towards an increase in 
absolute numbers of Leu2 positive and Leu3 positive cells in 
gastritis but these did not achieve statistical significance (p=0.09 
and p=0.08 respectively). There was no significant change in the 
Leu3:Leu2 ratio or any association with duodenitis.
The Influence of Helicobacter Pylori
The effects of H pylori infection was assessed in the gastric 
mucosa only since the organism was not identified in the duodenum. 
Assessment was performed on the study group and the control group in 
combination and separately.
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Leu2(duodenal)
Leu3(gastric)
Leu3(duodenal)
L3:L2(gastric)
L3:L2(duodenal)
TABLE 20
T LYMPHOCYTE SUBSETS, RENAL FUNCTION 
AND IMMUNOSUPPRESSION
CORRELATION COEFFICIENT
Cydosporine Prednisolone Urea 
-0.282 0.043 -0.252
0.14 0.16 -0.119
-0.294 0.268 -0.224
-0.166 -0.104 0.42
-0.31 0.45 0.45
-0.197 -0.45 0.54**
* p = 0.04
** p = 0.03
Creatinine
-0.254
- 0.098
-0.146
0.52*
-0.307
0.54**
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TABLE 21
Leu2
Leu3
L3:L2
T LYMPHOCYTE SUBSETS 
GASTRITIS AND DUODENITIS
Gatritis No Gastritis Duodenitis No Duodenitis 
(N=5) (N=10) (N=8) (N=7)
211 94 92 83
267 149 207 178
1.97 1.59 2.37 2.82
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There was no significant difference in the absolute numbers of 
Leu3 positive cells or the Leu3sLeu2 ratio in the H pylori positive 
patients when compared to the H pylori negative patients. There was 
a tendency for the numbers of Leu2 positive cells to be higher in the 
presence of H pylori, but this did not achieve statistical 
significance ([p=0.18] [table 22]). When the data for transplant 
recipients and controls was examined seperately no differences could 
be identified (table 23).
The Influence of Cytomegalovirus Infection
Data on gastroduodenal CMV was available for the study group 
only and are summarised in table 24. There was a significant 
increase in the absolute numbers of Leu3 positive cells in the CMV 
positive patients (p=0.0l6), although this was not reflected in any 
alteration of the Leu3:Leu2 ratio. The majority of CMV infection in 
the study group was in the duodenum (6 out of 8) and therefore the 
data was analysed for duodenal mucosa only. On this occassion there 
was no significant increase in the Leu3 population (table 25).
The data was also analysed with respect to serological evidence 
of active CMV infection and, once more, no significant relationship 
could be demonstrated (Tables 26,27)
TABLE 22
T LYMPHOCYTE SUBSETS AND HELICOBACTER PYLORI (A)
H pylori + H pylori -
(N=18) (N=12)
Leu2 163 114
Leu3 233 189*
L3:2 ratio 1-6 2.2
P=0.18
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TABLE 23
Leu 2 
Leu 3 
L3:L2
T LYMPHOCYTE SUBSETS AND HELICOBACTER PYLORI (B)
TRANSPLANT CONTROLS
H pylori + H pylori - H pylori + H pylori 
(N=9) (N=6) (H=9) (H=6)
150 107 177 121
204 165 263 212
1.80 1.68 1.47 2.98
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TABLE 24
T LYMPHOCYTE SUBSETS AND CYTOMEGALOVIRUS
CMV + CMV -
(N=8) (N=22)
Leu2 123 106
Leu3 267 164*
L3:L2 2.57 1.99
P=0.018 (Students t test)
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TABLE 25
T LYMPHOCYTE SUBSETS AND DUODENAL CYTOMEGALOVIRUS
CMV + CMV -
(N=6) (N=9)
Leu2 111 82
Leu3 225 170*
L3:L2 2.62 1.99
p=0.26 (Students t test)
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TABLE 26
GASTRIC T LYMPHOCYTE SUBSETS AND CMV SEROLOGY
CMV+ CMV-
(N=7) (N=6)
Leu2 120 172
Leu3 172 212
L3:L2 1.98 1.28
TABLE 27
DUODENAL T LYMPHOCYTE SUBSETS AND CMV SEROLOGY
CMV+ CMV-
(N=7) (N=6)
Leu2 73 89
Leu3 201 187
L3:L2 2.95 2.54
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Discussion
T Lymphocyte. Sub set 3 in Normal Gastroduodenal Mnnnaa 
Gastric
The findings are expressed as T cells per mm^. Information on 
the normal values are difficult to obtain from the current
literature. Information, however, can be obtained from control
subjects utilised in studies of abnormal gastric mucosa. Kaye et al 
studied mucosal T cell subsets in patients with pernicious anaemia by 
immunohistochemistry (223). Included in this publication were 12 
subjects with a normal gastric mucosa. The mean number of Leu3 
(T Helper) cells in this group were 147 + 97 and 292 + 71 for Leu2
(T Suppressor) subset. The authors also noted slight variations in
the distribution of T lymphocytes at different levels within the 
mucosa. In the study group in this thesis, however, the numbers were 
assessed for the entire biopsy specimen and were comparable to the 
figures reported above.
Duodenal
As with normal gastric mucosa the absolute numbers of T 
lymphocytes in normal duodenal mucosa must be obtained from control 
groups in studies of duodenal pathology. Jenkins et al studied 
duodenal biopsy specimens from patients with coeliac disease and 
included 20 patients with a normal duodenal mucosa (224). The 
results are expressed per mm^ but the subsets were counted separately 
for surface epithelium, crypt epithelium and lamina propria and were 
not calculated for the full thickness of the biopsy specimens. 
Arithmetically however, 89? of Leu3 and Leu2 lymphocytes were in the 
lamina propria with mean values of 255 and 103 respectively, giving
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a mean ratio of 2.07. These figures are comparable with our own for 
the full thickness of the duodenal mucosa.
Mucosal „_T .Lymphocyte Subsets in Transplant Reoipianta
Only one study has reported on T lymphocytes in the 
gastroduodenal mucosa of transplant recipients (225). This study 
differs from ours in two important respects. Firstly the patients 
were bone marrow recipients and may not be strictly comparable to our 
study group, and secondly, the results were expressed as cells per 
twenty crypts for the epithelium and as cells per grid area 
(0.0625mm‘::) for the lamina propria. It is possible, however to 
overcome this second problem by employing a conversion factor of 256
p
to express the T lymphocytes in the lamina propria per mm . The
p
authors found a total Leu3 count of 796/mm and a total Leu2 count of
727/mm^ giving a Leu3:Leu2 ratio of 1.09. The authors also
demonstrated an increase in the absolute numbers of both cell types
2 2in graft versus host disease, giving 2432/mm and 1735/mm 
respectively and a ratio of 0.71.
The absolute numbers in transplant recipients are higher than 
in the gastroduodenal mucosa of normal individuals and are increased 
significantly in graft versus host disease. It is difficult, 
however, to be certain of the importance of this in renal transplant 
recipients, since they have a much lower incidence of graft versus 
host disease and the immunosupressive regime is very different. The 
figures are obviously widely at variance with our own data for 
transplant recipients.
150
The Relafc.iPHahi.P., -tQ ftsQel Function and Immunosuppression
There was a significant positive correlation between the Leu3 
subset and serum creatinine in the duodenal mucosa and a significant 
positive correlation between the Leu3iLeu2 ratio in the duodenal 
mucosa and both urea and creatinine. This may be due to the 
relationship between renal function and cylosporine levels. In the 
study group there was a weak negative correlation between 
cyclosporine levels and renal function. This would mean that high 
urea and creatinine levels tend to be associated with a decreased 
serum cyclosporine level. There was, however, no significant 
relationship between the T lymphocyte subsets and either cyclosporine 
levels or prednisolone dose.
The Influence of H Pvlori on Mucosal T Cell Subsets
Information on the local T cell response to H pylori is 
difficult to come by in the literature. At present only one report, 
published as an abstract, is available for comparison with our work 
(109). This report by Rathbone et al studied Leu3 and Leu2 subsets 
in the gastric mucosa of normal individuals and those with H pylori
associated gastritis.
The authors reported an increase in the absolute numbers of 
Leu3 (T Helper) cells in the lamina propria of patients with H pylori 
gastritis and a decrease in Leu2 (T Suppressor) cells. They also 
identified an increased percentage of Leu3 lymphocytes expressing the 
CD7 marker which is indicative of T cell blastogenesis, suggesting 
activation of a cell mediated response, presumably to H pylori.
In our data there was an increase in the absolute numbers of
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Leu 3 positive cells in patients with H pylori (233 v 189). This did 
not, however, achieve statistical significance(p=0.18)
The Influence of Cytomegalovirus on Mucosal T Cell Subsets
There is no guidance in the literature on the expected pattern 
of T lymphocyte subsets in the gastroduodenal mucosa in 
cytomegalovirus infection. There are, however, many reports of 
circulating T lymphocyte subpopulations accompanying CMV infection in 
the general population and in transplant recipients.
Maher et al demonstrated inversion of the Leu3: Leu2 ratio in 
transplant recipients with CMV infection (226). This inversion was 
frequently seen before a rise in antibody titres and in some cases 
remained inverted for several years. This finding was similar to 
that of Dafoe, who further demonstrated that the inversion was due to 
an absolute increase in the Leu2 subset (227). The finding of 
increased Leu2 cells was confirmed by Schooley et al (228). They 
also found that inversion of the Leu3:Leu2 ratio was prolonged in 
cadaveric transplants, but was transient in living related donor 
transplants and was associated only with active CMV infection. This 
difference was presumed to be due to the less aggressive 
immunosuppression in the latter group.
Not all authors, however, have demonstrated this feature. Von 
Es et al, in a large series, found no change in the Leu3:Leu2 ratio 
with CMV infection (229), findings confirmed by Rinaldo (163).
In one study of gastrointestinal CMV infection Brouillete et al 
demonstrated an inversion of the Leu3sLeu2 ratio (230). This 
difference was observed in peripheral blood lymphocytes, and the
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authors did not study mueosal T lymphocytes.
In the study group of this thesis there was an increase in the 
Leu3 subset in CMV infection, but no change in the Leu3iLeu2 ratio. 
The majority of CMV in the study group was in the duodenal mucosa and 
when the gastric mucosal lymphocyte counts were excluded from the 
analysis the difference was no longer significant. It may be, 
therefore, that the former result was spurious or that removal of the 
gastric CMV reduced the numbers so that statistical significance was 
not achieved. We certainly did not observe the increase in the Leu2 
subset or inversion of the Leu3:Leu2 ratio, which has been reported 
in peripheral blood, reflected in the gastric or duodenal mucosa, nor 
was there any relationship between mucosal T cell subsets and 
serological evidence of active CMV infection.
Conclusions
The results of T lymphocyte subset analysis are disappointing 
and inconclusive. There were minor trends identified but no 
important significant results. It is particularly disappointing that 
no convincing relationship could be demonstrated between mucosal T 
lymphocytes and either CMV or H pylori infection. While the systemic 
T cell response to CMV infection has been described extensively the 
importance of the T cell response to Eelicobacter infection is 
unknown and the results of this study have not clarified the 
situation.
There are perhaps two important reasons for these inconclusive 
results. The first relates to the small numbers of patients involved. 
There were 15 patients in each group giving a total of sixty
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individual biopsies each of which was examined for Leu2 and Leu3. 
The difficulties may have arisen when the groups were subdivided into 
transplant and controls and further divided into duodenal and gastric 
mucosa, thereby reducing the numbers to fifteen in each group. A 
second and possibly more important reason is the subjectivity 
involved in counting the T cells. There is no automated way in which 
this can be achieved and counting has to be done manually. All of 
our slides were counted by two independent observers and the mean 
error was 36?, highlighting the poor reproduceability of the 
technique. With this margin of error relatively small differences 
may be lost.
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PART III
CONCLUSIONS
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CHAPTER 8
CONCLUSIONS
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THE PREVALENCE OF UPPER GI PATHOLOGY AND DYSPEPSIA
Although the prevalence of peptic ulceration and the incidence 
of complications in transplant recipients has been recognised for 
many years, the importance of non-ulcer dyspepsia has been poorly 
recognised and the high prevalence of mucosal inflammatory lesions 
has only been appreciated recently.
This study has identified symptomatic dyspepsia in 60? of renal 
transplant recipients which was resistant to H2 receptor antagonist 
therapy in 67?. The prevalence of peptic ulceration was 12? in the 
study group as a whole and 20? in the symptomatic group, which is 
consistent with previous reports (1,9,10,12). This does, however, 
mean that 80? of patients with dyspeptic symptoms did not suffer from 
peptic ulceration at the time of endoscopy.
A striking feature was the high prevalence of mucosal 
Inflammatory lesions but, even taking these into account, 30? of the 
dyspeptic patients had no identifiable abnormality in the upper 
gastrointestinal tract. A further problem is the high prevalence of 
mucosal inflammatory lesions in the asymptomatic group.
There was a trend for gastritis to be commoner in symptomatic 
patients but this did not achieve statistical significance. It may 
be, however, that a significant association would have been 
demonstrated if a larger study population had been available. The 
relationship of gastritis to symptomatic dyspepsia has been discussed 
in Chapters 2 and 4 and the subject remains controversial. Evidence 
based on the eradication of H pylori would suggest, however, that 
resolution of gastritis is accompanied by improvement in dyspeptic 
symptoms (73, 209, 231).
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The most common abnormality detected was duodenitis and, as 
with gastritis, its role in dyspepsia has been the subject of some 
debate. Cheli et al in 1982 suggested that duodenitis was very 
uncommon in asymptomatic individuals (204), although this was at 
variance with other reports (205,232). The results from this study 
would suggest that duodenitis does occur in asymptomatic transplant 
recipients.
In view of these uncertainties it would be possible to argue 
that gastritis and duodenitis are not important in the aetiology of 
dyspepsia in transplant recipients. This point of view, however, is 
not necessarily valid and it is entirely reasonable to suggest that 
gastritis and duodenitis can give rise to symptoms in some patients, 
but not in others. It is widely recognised that asymptomatic peptic 
ulcer occurs commonly in the general population and yet few people 
would argue that peptic ulceration is not responsible for symptoms in 
many patients.
It seems, reasonable, therefore, to suggest that gastritis and 
duodenitis are responsible for dyspeptic symptoms in a significant 
proportion of transplant recipients and that they are also identified 
in patients who are asymptomatic. This is especially true since the 
mechanism of dyspeptic pain is poorly understood and it is recognised 
that many patients with peptic ulceration are asymptomatic (233) •
Identification of the pathological processes highlighted above 
does not however explain their aetiology. The relationship of these 
abnormalities to H pylori and Cytomegalovirus will be discussed in 
the following sections.
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THE ROLE OF HELICOBACTER PYLORI
The overall prevalence of H pylori in the study group was 48$ 
and the organism was identified in 65$ of those with symptomatic 
dyspepsia. The problems in obtaining a truly representative control 
group give rise to difficulty in interpreting the importance of the 
absolute prevalence, since the organism is widespread in the general 
population. Current data, however, would suggest that the prevalence 
is higher than would be expected in an age matched group of normal 
individuals (111, 212, 213). It would be an attractive theory to 
suggest that H pylori is found more commonly in transplant recipients 
because of immunosuppression and poor renal function. Such a 
relationship was not demonstrated in the study group, although there 
was probably insufficient variation in renal function and the 
immunosuppressive regimes to highlight any significant association.
In practice, however, the absolute prevalence of H pylori is 
of lesser importance than its relationship to gastritis and dyspeptic 
symptoms. In the study group there was a significant association 
with gastritis, gastric ulceration and with symptomatic dyspepsia.
The importance of H pylori, therefore, lies in its role in 
gastritis, non ulcer dyspepsia and gastric ulceration which is 
consistent with its role in the general population. This study has 
confirmed the high prevalence of dyspepsia in transplant recipients 
and has demonstrated a significant association between dyspeptic
symptoms and H pylori colonisation.
It would be premature to advocate widespread use of colloidal 
bismuth and antibiotics in the routine management of transplant 
dyspepsia at this time. Further work must be carried out using if
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necessary, non invasive methods of assessing H pylori colonisation. 
This should be followed up by controlled trials of therapy with 
monitoring of the symptomatic response to eradication of 
Helicobacter. In clinical practice the management of transplant 
dyspepsia still requires pre-treatment investigation, ideally by 
endoscopy, along with biopsy of the gastric antrum for the assessment 
of H pylori coloniseation.
THE ROLE OF CYTOMEGALOVIRUS
Cytomegalovirus was identified in 48$ of the study group 
compared with 11$ of the normal controls. The distribution of CMV in 
the upper GI tract was not uniform and the prevalence of virus in the 
gastric mucosa was not significantly different in the study group and 
in the control group. The major difference, however, was in the 
distribution in the duodenal mucosa. Virus was identified in the 
duodenal mucosa in 39$ of transplant recipients but in only 8$ of the 
control group (p=0.006).
The virus was identified by cytomegalic changes in seven 
patients but by immunohistochemistry in nineteen. This feature has 
been reported in other tissues but has not been previously reported 
in the GI tract (195*196). The implication of this finding, 
therefore, is that previous reports relying on histology alone are 
likely to have underestimated the prevalence of CMV infection 
(8,11,142).
The prevalence of cytomegalovirus in the upper GI tract of 
transplant recipients has been reported previously to be between 12$ 
and 62$ (8,11,19,142). The results of this study obviously lie
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within this range notwithstanding the different detection methods. 
Prior to the work of this thesis, however, the prevalence in the 
normal population was unknown and it was not possible to draw any 
definite conclusions regarding the possible pathogenic effect of the 
virus in transplant recipients.
Identification of CMV in the upper gastrointestinal tract is 
not, however, proof of a pathogenic role. The only pathological 
process which was associated with CMV infection was duodenitis. 
There were sixteen patients in the study group with histological 
duodenitis, eleven of whom had CMV identified in the duodenal mucosa. 
More significant, perhaps, was the fact that only two patients with 
duodenal CMV had a normal mucosa.
Duodenitis has only been reported in small numbers in 
transplant recipients although it is a common problem in the general 
population and is generally thought to be part of the spectrum of 
duodenal ulceration (104,232). The possibility that duodenitis in 
the general population is due to cytomegalovirus was therefore 
considered and control tissue was obtained from non transplant 
recipients with duodenitis. No virus was identified in these
patients (p<0.001).
If CMV is a cause of duodenitis it is only of importance if it 
is related to symptoms. In the study group in this thesis there was 
no association of CMV and duodenitis with symptomatic dyspepsia. In 
the light of studies in the general population this is perhaps rather 
surprising since duodenitis is an uncommon finding in asymptomatic 
individuals (204,205). It is of course possible to suggest that 
duodenitis may give rise to symptoms in some patients and may be
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asymptomatic in others. This is certainly the case in Helicobacter 
associated gastritis which has been studied extensively in recent 
years.
Having established a statistical link between duodenitis and 
CMV infection there is still the question of its causal role. 
Unfortunately it is not possible to give a definite answer to this 
question based on the results of this work. Cytomegalovirus was not 
identified in duodenitis from normal control subjects but it is 
possible that its identification in the transplant recipients is 
merely a manifestation of the high prevalence of the virus in this 
group. To prove a causal role it would be necessary to establish 
that eradication of the virus is accompanied by histological 
improvement in the duodenal mucosa and this has not been done. It 
could indeed be argued that this type of study is not likely to be 
performed since CMV infection is difficult to treat and the toxicity 
of the chemotherapy is not justified where the symptoms are generally 
mild.
There is certainly no evidence to support the view that CMV is 
implicated in the pathogenisis of peptic ulceration in transplant 
recipients as suggested by some authors (8,11,142). The prevalence 
of peptic ulceration in the study group was 12^  which is in keeping 
with the prevalence in other series and it seems likely that a much 
larger study group would be required along with appropriate controls 
to investigate a link with peptic ulceration.
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THE ROLE OF HERPES SIMPLEX VIRUS
The findings for Herpes simplex virus were negative and the 
virus was not identified in the gastroduodenal mucosa. This does not 
necessarily mean that Herpes simplex is not present in the upper GI 
tract. Previous reports in non transplant immunosuppressed patients 
have identified the virus in the oesophagus but have identified 
gastric involvement in only 2$ of patients with herpetic oesophagitis 
(176). There is, however, no evidence of Herpes simplex virus in 
either the gastric or duodenal mucosa of the study group or the 
control subjects.
MUCOSAL T LYMPHOCYTE SUBSETS
Prior to the beginning of this study it was hoped that viral or 
bacterial infection in transplant recipients would be accompanied by 
changes in the normal pattern of mucosal lymphocytes. It was an 
attractive theory to suggest that the upper gastrointestinal 
complications were due to the immunosuppressed condition of these 
patients and that a study of the mucosal lymphocyte subsets would 
shed some light on the immune response to these infective agents. 
This was particularly important with respect to H pylori where the 
importance of the cell mediated response is unclear.
Unfortunately the data obtained from this work has done little 
to clarify these points. There was no significant difference in the 
T cell subsets between the study group and the control group, 
although the study group are undoubtedly immunosuppressed. It may be 
that a simple numerical process is not sufficiently sensitive to 
detect differences in immune function. It is also probable that the
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subjectivity of cell counting is not sufficiently accurate to detect 
relatively small differences.
The data did demonstrate an increase in the Leu3 subset in H 
pylori infection, previously reported by Rathbone et al (109), 
although this did not achieve statistical significance.
FINAL CONCLUSIONS
This study has confirmed a relatively high prevalence of peptic 
ulceration in transplant recipients which is in keeping with previous 
reports. It has also highlighted a high prevalence of non ulcer 
dyspepsia, gastritis and duodenitis which have been poorly recognised 
in the past.
Antral gastritis was significantly associated with H pylori 
colonisation and the organism was identified in 48% of the study 
group. H pylori was also significantly associated with gastric 
ulceration and dyspeptic symptoms. This prevalence is likely to be 
higher than would be expected in an age matched group of unselected 
non transplant recipients. There is, however, no clear evidence from 
the study that abnormalities of mucosal T lymphocytes contribute to 
an increased risk of H pylori infection.
Duodenitis was significantly associated with Cytomegalovirus in 
the duodenal mucosa although neither of these factors appeared to be 
related to symptomatic dyspepsia. Once more there was no clear 
evidence of mucosal lymphocyte abnormalities associated with CMV 
infection.
In practical terms dyspepsia in transplant recipients is a 
multifactorial process which is likely to involve an interaction of
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acid secretion, corticosteroids and Helicobacter pylori, and may also 
involve CMV infection in the duodenum. Dyspepsia in this group of 
patients should be fully investigated and the high prevalence of 
mucosal inflammatory lesions would suggest that this would be best 
achieved by endoscopy and biopsy for the assessment of H pylori.
It is difficult to be certain of the best way to investigate 
further the role of CMV in duodenitis and there is insufficient 
information on the response of duodenitis to H2 receptor antagonists 
in this group to be sure that it is the same pathological process 
seen in the general population. Further work is required to study the 
effects of H pylori eradication on symptoms and on histological 
gastritis and this would appear to be the most promising avenue for 
further research.
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